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  todos	  estes,	  o	  meu	  sincero	  agradecimento.	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Abstract	  	  	  	   Gaucher	  disease	  is	  the	  most	  common	  lysosomal	  storage	  disorder	  and	  may	  present	   systemic	   and	   neurological	   symptoms.	   It	   is	   caused	   by	  mutations	   in	   the	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Resumo	  alargado	  	   A	  doença	  de	  Gaucher	  é	   considerada	  uma	  patologia	   rara,	  no	  entanto	   tem	  vindo	  a	  atingir	  várias	  populações	  e	  famílias	  com	  uma	  taxa	  crescente,	  sendo	  uma	  doença	  que	  afecta	  adultos,	  crianças	  e	  bebés.	  	  Esta	   patologia	   divide-­‐se	   principalmente	   em	   três	   tipos:	   o	   tipo	   1	   que	   se	  caracteriza	   por	   afectar	   tanto	   crianças	   como	   adultos,	   podendo	   estes	   indivíduos	  viver	   apenas	   durante	   a	   sua	   infância	   ou	   eventualmente	   atingir	   a	   idade	   adulta.	  Uma	   das	   principais	   características	   que	   identificam	   o	   tipo	   1	   e	   diferem-­‐no	   dos	  outros	  tipos	  da	  doença	  de	  Gaucher	  é	  o	  facto	  de	  o	  sistema	  nervoso	  central	  não	  ser	  afectado.	   O	   tipo	   2	   caracteriza-­‐se	   por	   afectar	   maioritariamente	   crianças,	  possuindo	  uma	  esperança	  média	  de	  vida	  curta,	  tendo	  em	  conta	  que	  os	  indivíduos	  vivem	   em	   média	   cerca	   de	   nove	   meses.	   Ocorre	   no	   tipo	   2,	   entre	   outras	  complicações,	  o	  envolvimento	  severo	  do	  sistema	  nervoso	  central.	  O	  tipo	  3	  afecta	  tanto	  crianças	  como	  adultos,	  sendo	  a	  esperança	  média	  de	  vida	  dos	  indivíduos	  o	  período	  da	  infância	  e,	  em	  alguns	  casos,	  a	  idade	  jovem	  adulta.	  No	  tipo	  3	  o	  sistema	  nervoso	   central	   está	   afectado,	   assim	   como	   no	   tipo	   2.	   Existe	   ainda	   o	   tipo	  intermediário,	  entre	  o	  tipo	  2	  e	  o	  tipo	  3,	  que	  se	  inicia	  com	  idade	  avançada,	  porém	  com	  rápida	  progressão	  de	  complicações	  neurológicas	  (Grabowski,	  2008).	  A	   presente	   doença	   é	   classificada	   como	   doença	   de	   depósito	   lisossómico,	  devido	   ao	   armazenamento	   que	   existe	   nos	   lisossomas	   das	   células	   intituladas	  células	  de	  Gaucher,	  onde	  decorre	  uma	  acumulação	  do	  substrato	  da	  enzima	  que	  sofre	   mutações.	   O	   gene	   GBA	   dá	   origem	   à	   enzima	   glucocerebrosidase,	   porém	  quando	   surgem	   mutações	   neste	   gene	   sucedem	   alterações	   no	   funcionamento	  normal	  da	  enzima.	  Atualmente	  estão	  referenciadas	  mais	  de	  250	  mutações	  neste	  gene,	   as	   quais	   contribuem	   para	   a	   atividade	   reduzida	   da	   enzima	  glucocerebrosidase.	   A	   anomalia	   na	   clivagem	   normal	   da	   enzima	   possibilita	   ao	  substrato	  desta	  acumular-­‐se	  nos	  macrófagos,	  originando	  as	  denominadas	  células	  de	   Gaucher.	   Este	   armazenamento	   sucede	   principalmente	   no	   baço,	   fígado	   e	  medula	   óssea.	   Como	   resultado	   dessa	   acumulação,	   alguns	   órgãos	   são	   afectados	  provocando	  a	  doença	  de	  Gaucher	  (Grabowski,	  2008).	  A	   doença	   de	   Gaucher	   tem	   sido	   foco	   de	   investigação	   para	   métodos	  terapêuticos	   da	  mesma,	   uma	   vez	   que	   as	   terapias	   que	   existem	   atualmente	   não	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possuem	  um	  alcance	  geral	  por	  parte	  de	   todos	  os	  pacientes,	   visto	  que	  as	   atuais	  formas	   de	   tratamento	   possuem	   um	   elevado	   custo	   e	   algumas	   delas	   não	   tratam	  completamente	   todos	   os	   tipos	   da	   doença.	   Assim,	   surge	   a	   necessidade	   de	  implementar	   novas	   terapias	   que	   possam	   combater	   as	   atuais	   limitações	   dos	  tratamentos	  convencionais	  para	  doença	  de	  Gaucher	  (Tropak	  et	  al.,	  2008).	  Deste	  modo,	   sucede	   uma	   nova	   estratégia	   terapêutica	   para	   esta	   doença:	  um	  tratamento	  que	  utiliza	  chaperonas,	  proteínas	  que	  aumentam	  a	  atividade	  da	  glucocerebrosidase,	   a	   enzima	   mutada	   na	   doença	   de	   Gaucher.	   Este	   método	  inovador	   pretende	   aumentar	   a	   eficácia	   da	   terapia,	  melhorando	   os	   seus	   efeitos	  nos	  pacientes	  e	  alcançando	  todos	  os	   tipos	  existentes	  da	  doença.	  As	  chaperonas	  ajudam	  a	  estabilizar	  o	  folding	  da	  enzima	  mutada,	  aumentando	  e	  corrigindo	  o	  seu	  tráfego	   no	   retículo	   endoplasmático	   de	   forma	   a	   que	   exerça	   corretamente	   a	   sua	  função.	  Este	  processo	  tem	  sido	  investigado	  com	  o	  objectivo	  de	  melhorar	  as	  atuais	  condições	  dos	  pacientes	  da	  doença	  de	  Gaucher	  (Tropak	  et	  al.,	  2008).	  É	  no	  âmbito	  da	  presente	  investigação	  na	  doença	  de	  Gaucher	  que	  se	  insere	  este	   trabalho	   experimental,	   o	   qual	   tem	   como	   objectivo	   testar	   os	   efeitos	   das	  chaperonas	   na	   atividade	   da	   glucocerebrosidase	   em	   fibroblastos	   de	   pacientes	  com	  diferentes	  genótipos.	  	  Os	   fibroblastos	   de	   diferentes	   genótipos	   foram	   submetidos	   a	   um	  tratamento	  com	  as	  chaperonas	  medindo	  a	  concentração	  e	  a	  respectiva	  atividade	  da	  enzima	  glucocerebrosidase.	  Os	  resultados	  obtidos	  confirmam	  que	  em	  certos	  casos,	   as	   chaperonas	   utilizadas	   aumentam	   de	   facto	   a	   atividade	   da	   enzima	  mutada,	   revelando	   ser	   um	  método	   promissor	   para	   o	   tratamento	   da	   doença	   de	  Gaucher.	  O	  presente	  estudo	  demonstra	  ainda	  que	  o	  aumento	  sucede	  consoante	  a	  chaperona	   utilizada	   e	   a	   respectiva	   concentração	   da	   mesma.	   Existem	   também	  alterações	  devido	  aos	  diferentes	  genótipos	  das	   linhas	  celulares	  utilizadas	  neste	  estudo.	  	  	   No	   futuro,	   as	   técnicas	   estabelecidas	  para	  medição	  da	   concentração	   e	   da	  atividade	  da	  glucocerebrosidade	  poderão	  ser	  utilizadas	  para	  medir	  os	  efeitos	  das	  chaperonas	  na	  enzima	  mutada	  em	  neurónios	  diferenciados	  de	  IPSc	  de	  pacientes	  com	   a	   doença	   de	   Gaucher.	   A	   fim	   de	   estabelecer	   o	   potencial	   desta	   opção	  terapêutica	   para	   a	   doença	   de	   Gaucher,	   particularmente	   para	   as	   suas	   formas	  neuropáticas.	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Index	  of	  Abbreviations:	  
	  
	  
	  -­‐	  4MU	  	  	   4-­‐methyl-­‐umbelliferone;	  	  -­‐	  aa	  	   	   Amino	  acids;	  	  -­‐	  Ala	   	   Alanine;	  	  -­‐	  Asn	   	   Asparagine;	  	  -­‐	  bp	   	   Base	  pairs;	  	  -­‐	  BSA	  	  	  	   Bovine	  serum	  albumin;	  	  -­‐	  DMEM	  	  	   Dulbecco’s	  modified	  eagle’s	  medium;	  	  -­‐	  ECL	  	   	  	   Enhanced	  chemiluminescence	  reagent;	  	  -­‐	  EET	  	  	  	   Enzyme	  enhancement	  therapy;	  	  -­‐	  ER	  	  	   	   Endoplasmic	  reticulum;	  	  -­‐	  ERT	  	  	  	   Enzyme	  replacement	  therapy;	  	  -­‐	  FBS	  	  	   	   Fetal	  bovine	  serum;	  	  -­‐	  FS++	  	  	   Immortal	  human	  fibroblast	  cell	  line	  used;	  	  -­‐	  GBA	  	  	  	   Glucocerebrosidase;	  	  -­‐	  GBA	   	   Gene	  GBA;	  	  -­‐	  GBAP	  	  	   Pseudo	  gene	  GBA;	  	  -­‐	  GD	  	  	   	   Gaucher	  Disease;	  	  -­‐	  GD1	   	   1st	  Fibroblast	  cell	  line	  from	  GD	  patients	  (with	  type	  2	  GD);	  	  -­‐	  GD2	   	   2nd	  Fibroblast	  cell	  line	  from	  GD	  patients	  (with	  type	  2	  GD);	  	  -­‐	  GD3	   	   3rd	  Fibroblast	  cell	  line	  from	  GD	  patients	  (with	  type	  2	  GD);	  	  -­‐	  GD4	   	   4th	  Fibroblast	  cell	  line	  from	  GD	  patients	  (with	  type	  2	  GD);	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-­‐	  GDT1	  	  	   Gaucher	  disease	  type	  1;	  	  -­‐	  GDT2	  	   Gaucher	  disease	  type	  2;	  	  -­‐	  GDT3	  	   Gaucher	  disease	  type	  3;	  	  -­‐	  Glu	   	   Glutamic	  acid;	  	  -­‐	  GSL	  	   	   Glycosphingolipids;	  	  -­‐	  HFF	  	  	  	   Primary	  cell	  line	  from	  a	  human	  foreskin	  dissection	  used;	  	  -­‐	  hr	   	   Hour(s);	  	  -­‐	  IPSc	  	  	  	   Induced	  pluripotent	  stem	  cells;	  	  -­‐	  kb	   	   Kilo	  basepair;	  	  -­‐	  Leu	   	   Leucine;	  	  -­‐	  LU	   	   Light	  units;	  	  -­‐	  min	   	   Minutes;	  	  -­‐	  mRNA	   Messenger	  RNA;	  	  -­‐	  nm	   	   Nanometers;	  	  -­‐nmol	   	   Nanomoles;	  	  -­‐	  PBS	  	  	   	   Phosphate	  buffered	  saline;	  	  -­‐	  PC	  	  	   	   Phosphate	  Citrate;	  	  -­‐	  PCR	  	   	   Polymerase	  chain	  reaction;	  	  -­‐	  PCs	  	  	   	   Pharmacological	  Chaperones;	  	  -­‐	  PE	  	   	   Protein	  extract;	  	  -­‐	  Pro	   	   Proline;	  	  -­‐	  PVDF	  	   	  Polyvinylidene	  difluoride	  membrane;	  	  -­‐	  rpm	   	   Rotation	  per	  minute;	  	  -­‐	  RT	   	   Room	  temperature;	  	  -­‐	  Ser	   	   Serine;	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  -­‐	  SRT	  	  	  	  	   Substrate	  reduction	  therapy;	  	  -­‐	  TBST	  	   Tris-­‐buffered	  saline	  and	  tween	  20;	  	  -­‐	  WB	  	  	   	   Western	  blot;	  	  -­‐	  WT1	  	  	   First	  wild-­‐type	  cell	  line	  used;	   	  	  -­‐	  WT2	  	  	   Second	  wild-­‐type	  cell	  line	  used;	  	  -­‐	  µg	   	   Micrograms;	  	  -­‐	  µl	   	   Microliters;	  	  -­‐	  µM	   	   Micromolar.	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  1	  -­‐	  Introduction	  	  




1.1	  Disease	  	  	   Lysosomal	  storage	  disorders	  (LSD)	  are	  a	  group	  of	  rare	  diseases	  caused	  by	  accumulation	   of	   a	   diverse	   set	   of	   metabolic	   intermediates	   in	   cell	   lysosomes.	  Gaucher	   disease	   (GD)	   is	   a	   lysosomal	   storage	   disorder	   that	   can	   present	   both	  systemic	  and	  neurological	  symptoms	  and	  is	  inherited	  in	  an	  autosomal	  recessive	  way.	   It	   is	   the	  most	   common	  LSD,	  with	  a	  prevalence	  of	   approximately	  1/75000	  live	   births	   worldwide.	   However	   the	   disease	   presents	   higher	   prevalence	   in	  specific	   ethnic	   groups.	   GD	   is	   caused	   by	   mutations	   in	   the	   gene	   coding	   for	  glucocerebrosidase	   (GBA),	   enzyme	   that	   catalyses	   the	   breakdown	   of	  sphingolipids	  in	  the	  cell	  lysosome.	  As	  the	  result	  of	  this	  enzymatic	  deficiency,	  GBA	  substrates	  accumulate	  in	  the	  lysosome	  (Beck,	  2007;	  Bohra	  &	  Nair,	  2011;	  Butters,	  2007;	  Vairo	  et	  al.,	  2013;	  Zhao,	  Keddache,	  Bailey,	  Gl,	  &	  Gaucher,	  2003).	  	  
1.2	  Historical	  Background	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Neurologic	  symptoms	  (in	  neuronopathic	  subtypes)	  Pulmonary	  involvement	  
Skeletal	  involvement	  
Thrombocytopenia	  and	  anaemia	  Hepatosplenomegaly	  
1.3	  Clinical	  Presentation	  	   Gaucher	   disease	   is	   a	   rare	   disorder	   in	   which	   patients	   can	   show	   a	  multisystemic	  clinical	  presentation,	  with	  a	  range	  of	  symptoms	  affecting	  a	  broad	  range	  of	  tissues	  and	  organs.	  Its	  symptoms	  can	  be	  broadly	  divided	  into	  systemic,	  affecting	  liver,	  spleen,	  bone	  marrow,	  lungs	  and	  skeletal	  system,	  and	  neurological,	  affecting	  the	  central	  nervous	  system	  (Figure	  1)(Cassinerio,	  Graziadei,	  &	  Poggiali,	  2013;	   G.	   A.	   Grabowski,	   Barnes,	   &	   Burrow,	   2011;	   Gupta,	   Oppenheim,	   Kauvar,	  Tayebi,	   &	   Sidransky,	   2011).	   Depending	   on	   the	   clinical	   presentation,	   Gaucher	  disease	  has	  been	  classically	  divided	  in	  three	  main	  types.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  Figure	   1	   -­‐	   Main	   symptoms	   observed	   in	   Gaucher	   Disease.	   Adapted	  
from:	   “Hepatosplenomegaly:	   MedlinePlus	   Medical	   Encyclopedia	   Image,”	  2012.	  	  
	  
1.3.1	  Type	  1	  
	   	  Gaucher	  disease	  type	  1	  (GDT1)	  is	  the	  most	  common	  form	  of	  the	  disease	  (~90%	   of	   Gaucher	   disease	   patients).	   Its	   onset	   is	   variable	   and	   can	   occur	  anywhere	   from	   20	   years	   of	   age	   and	   older.	   The	   typical	   major	   symptoms	   are	  hepatosplenomegaly,	   pancytopenia,	   leucopenia,	   bone	   loss,	   vertebrae	   colapse,	  pulmonar	  disease,	  cholelithiasis,	  cardiac	  and	  renal	  complications	  and	  secondary	  neurological	  complications	  related	  to	  bone	  disease	  (Figure	  1).	  The	  most	  common	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sign	   in	   type	   1	   variants	   is	   asymptomatic	   splenomegaly.	   Spleen	   volume	   can	  become	  50	  times	  bigger	  than	  the	  normal	  size,	  inducing	  early	  satiety	  and	  causing	  mechanical	   interference	   with	   respiratory	   function.	   Over	   50%	   of	   the	   patients	  present	   hepatomegaly.	   In	   certain	   patients	   the	   liver	   can	   become	   massive,	  overflowing	  much	  of	  the	  abdomen.	  A	  majority	  of	  patients	  (75%-­‐90%)	  have	  bone	  injuries,	   the	  most	   frequent	   being	   the	   Erlenmeyer	   flask	   deformity	   of	   the	   distal	  femur.	   Furthermore,	   destruction	   of	   the	   marrow	   cavity,	   lytic	   changes	   in	   bone	  cortex	   and	   osteoporosis/osteopenia	   may	   be	   observed.	   	   Osteopenia	   is	   a	  progressive	  process	  that	  is	  more	  suitable	  to	  be	  noticed	  in	  adulthood.	  There	  is	  a	  consistent	   absence	   of	   primary	   central	   nervous	   system	   disease	   in	   GDT1.	   Life	  expectancy	  for	  GDT1	  patients	  is	  decreased	  (68	  years	  vs.	  77	  years),	  regardless	  of	  gender	  (Cassinerio	  et	  al.,	  2013;	  G.	  A.	  Grabowski	  et	  al.,	  2011;	  Gupta	  et	  al.,	  2011).	  	  
	  
1.3.2	  Type	  2	  
	   Gaucher	   disease	   type	   2	   (GDT2),	   also	   called	   ‘neuronopathic’	   is	   the	  most	  severe	  form	  of	  the	  disease.	  Onset	  occurs	  shortly	  after	  birth	  with	  first	  symptoms	  occurring	  between	  2-­‐6	  months	  of	  age.	  Typically,	  patients	  present	  growth	  arrest,	  bulbar	  and	  pyramidal	   signs,	   oculomotor	  abnormalities	   and	   severe	  neurological	  manifestations,	   including	   central	   nervous	   system	   symptoms	   such	   as	   spasticity,	  and	   eye	   paralysis.	   The	   cognitive	   involvement	   is	   general	   and	   usually	   starts	   as	  developmental	   stagnation,	   but	   later	   progresses	   to	   neurological	   degeneration.	  Mechanisms	  underlying	  neurodegeneration	  remain	  poorly	  understood.	  Patients	  gradually	  evolve	  microcephaly,	  stridor,	  trismus	  and	  epilepsy.	  Most	  children	  with	  Gaucher	   disease	   also	   develop	   hepatosplenomegaly,	   severe	   cachexia	   and	   joint	  contractures.	  Muscle-­‐skeletal	   disease	   is	   normally	   not	   as	   evident	   in	   GDT2	   as	   in	  other	  GD	  types.	  Patients	  eventually	  die	  of	  pneumonia	  or	  other	  infections,	  usually	  around	   2	   years	   of	   age.	   Severe	   cases	   show	   prenatal	   or	   perinatal	   symptoms.	  Prenatal	   symptoms	   include	   poor	   fetal	   movement,	   cardiomegaly,	   intrauterine	  growth	   retardation,	   non-­‐immune	   hydrops	   fetalis,	   splenomegaly	   and	  hepatomegaly,	   and	   joint	   contractures	   or	   arthrogryposis	   (as	   a	   consequence	   of	  fetal	   akinesia).	   Approximately	   35%	  of	   babies	   diagnosed	  perinatally	  with	  GDT2	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are	   dysmorphic,	   with	   low-­‐set	   ears,	   a	   small	   nose	   with	   a	   flat	   nasal	   bridge	   and	  hypertelorism	  (Cassinerio	  et	  al.,	  2013;	  G.	  A.	  Grabowski	  et	  al.,	  2011;	  Gupta	  et	  al.,	  2011).	  Fortunately,	  GDT2	  is	  relatively	  rare	  (~10%	  of	  cases	  of	  Gaucher	  disease	  –	  1:100	  000	  in	  the	  general	  population)	  (Cassinerio	  et	  al.,	  2013;	  G.	  A.	  Grabowski	  et	  al.,	  2011;	  Gupta	  et	  al.,	  2011).	  	  
	  
1.3.3	  Type	  3	  
	   Gaucher	   disease	   type	   3	   presents	   both	   systemic	   and	   neurological	  symptoms.	  It	  is	  the	  chronic	  form	  of	  the	  disease,	  having	  an	  earlier	  onset	  than	  type	  1,	  usually	  during	  childhood	  or	  early	  adulthood.	  The	  most	  common	  symptoms	  are	  hepatosplenomegaly,	  anaemia,	  thrombocytopenia,	  bone	  involvement,	  pulmonary	  infiltrates	  and	  esophageal	  varices	  associated	  with	  liver	  cirrhosis.	  The	  lifespan	  is	  severely	  reduced,	  with	  most	  patients	  dying	  in	  their	  4th	  decade	  of	   life.	  There	  are	  three	  subgroups	  of	   type	  3:	   type	  3a	  –	   is	  characterized	  by	  progressive	  myoclonic	  epilepsy	   and	   dementia;	   type	   3b	   -­‐	   presents	   systemic	   disease	   and	   neurologic	  manifestations	  largely	  limited	  to	  horizontal	  supranuclear	  gaze	  palsy;	  and	  type	  3c	  –	   presents	   neuropathic	   involvement	   with	   severe	   valvular	   and	   aortic	   arch	  calcifications	   (Cassinerio	  et	   al.,	   2013;	  G.	  A.	  Grabowski	   et	   al.,	   2011;	  Gupta	  et	   al.,	  2011).	  	  
1.3.4	  Phenotypic	  continuum	  (an	  intermediate	  phenotype	  between	  type	  2	  and	  type	  
3)	  	   There	   is	   an	   intermediate	   phenotype	   with	   onset	   later	   than	   usually	  identified	   in	   type	  2,	   however	  with	  much	   severe	  neurological	   involvement	   than	  commonly	  observed	   in	   type	  3.	  Signs	  and	  symptoms	  as	  horizontal	   supranuclear	  gaze	   palsy	   and	   refractory	  myoclonis	   seizures	  were	   described,	   as	   also	   as	   rapid	  decline	  due	  to	  these	  seizures	  in	  neuronal	  function	  with	  related	  ataxia,	  dementia	  and	  opisthotonus.	  Death	  occurs	  at	  3	  years	  old,	  caused	  by	  progressive	  brainstem	  involvement	  and	  aspiration	  pneumonia	  (Cassinerio	  et	  al.,	  2013;	  Goker-­‐Alpan	  et	  al.,	  2003;	  G.	  A.	  Grabowski	  et	  al.,	  2011;	  Gupta	  et	  al.,	  2011).	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1.4	  Genetics	  
1.4.1	  GBA	  gene	  
	   The	  GBA	  gene	  is	  located	  at	  chromosome	  1q21,	  contains	  11	  exons	  and	  10	  introns	  and	  is	  approximately	  7kb	  in	  length.	  The	  GBA	  gene	  location	  is	  represented	  in	  Figure	  2.	  Alternative	  splicing	  results	  in	  multiple	  transcript	  variants.	  The	  region	  surrounding	   human	   GBA	   has	   been	   found	   to	   be	   particularly	   rich	   in	   genes,	  including	   seven	   genes	   and	   two	   pseudo-­‐genes	   within	   a	   85kb	   region	   of	  chromosome	  1q.	  The	  putative	  TATA	  and	  CAAT	  like	  boxes	  of	  glucocerebrosidase	  promoter	  have	  been	  recognized	  about	  260	  bp	  upstream	  from	  the	  upstream	  ATG	  start	  codon	  (G.	  a	  Grabowski,	  2012).	  	  	  	  
	  	  
Figure	   2	   -­‐	   GBA	   gene	   location	   on	   the	   long	   (q)	   arm	   of	   chromosome	   1	   at	  
position	  21.	  Adapted	  from:	  “GBA	  -­‐	  glucosidase,	  beta,	  acid,”	  2014;	  NCBI,	  2014.	  	  	   Several	   different	   mRNA	   species	   have	   been	   detected	   on	   Northern	   blots,	  which	   can	   be	   attributed	   to	   splice	   variants,	   alternate	   polyadenylation	   sites,	   or	  transcription	  of	  the	  pseudo-­‐gene	  (G.	  a	  Grabowski,	  2012).	  	  The	   mRNA	   has	   2324bp	   that	   translates	   into	   a	   536-­‐aminoacid	   protein	  Glucocerebrosidase.	  There	  are	  3	  isoforms	  of	  the	  protein.	  In	  normal	  conditions	  it	  is	   trafficked	   to	   the	   lysosome,	   where	   it	   catalyses	   the	   breakdown	   of	   glycolipid	  gluosylceramide	   to	   ceramide	   and	   glucose.	   The	   protein	   has	   four	   glycosylation	  sites	  at	  Asn58,	  Asn98,	  Asn185,	  and	  Asn309	  and	  its	  catalytic	  residues	  are	  located	  at	  Glu274	  and	  Glu379.	  	  
GBA	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The	   tissue	   levels	   of	   GBA	   mRNA	   vary	   among	   different	   cell	   types,	   with	   high,	  moderate,	   low	   and	   negligible	   levels	   reported	   in	   epithelial,	   fibroblast,	  macrophage	  and	  B-­‐cell	   lines,	  respectively	  (Hruska,	  LaMarca,	  Scott,	  &	  Sidransky,	  2008).	  	  
	  
1.4.2	  GBA	  Pseudo-­‐gene	  
	   There	   is	   a	   5kb	   GBA	   pseudo-­‐gene	   (GBAP)	   that	   is	   located	   approximately	  16kb	  downstream	  from	  the	  GBA	  gene,	  on	  chromosome	  1.	  GBAP	  is	  transcribed,	  an	  unusual	   characteristic	   for	   a	   pseudo-­‐gene,	   but	   the	   open-­‐reading	   frame	   is	   short	  due	   to	   several	   stop	   codons.	   Nonetheless,	   it	   has	   maintained	   a	   high	   degree	   of	  homology	  with	  the	  functional	  gene,	  sharing	  approximately	  96%	  of	  the	  sequence	  in	  coding	  regions	  and	  the	  same	  organization	  of	  exons	  and	  introns.	  The	  different	  length	  of	  GBA	  and	  GBAP	  is	  explained	  by	  the	  presence	  of	  several	  Alu	  insertions	  in	  introns	  of	  GBA.	  The	  existence	  of	  this	  pseudo-­‐gene	  is	  significant,	  as	  recombination	  events	   between	   GBA	   and	   its	   pseudo-­‐gene	   can	   result	   in	   mutated	   GBA	   genes.	  Furthermore,	   the	  high	  degree	  of	   homology	   can	   complicate	   the	   identification	  of	  
GBA	  mutations.	  The	  pseudo-­‐gene	  carries	  a	  55-­‐bp	  deletion	  in	  exon	  9,	  which	  may	  be	  of	  use	  for	  molecular	  diagnostic	  applications	  (Hruska	  et	  al.,	  2008).	  
	  
1.4.3	  Genotype	  –	  Phenotype	  	   GBA	   carries	   out	   its	   function	   in	   the	   lysosome,	   the	   main	   site	   of	   cellular	  digestion.	   The	   complex	   molecules	   being	   digested	   can,	   ultimately,	   be	   external	  material	   phagocytized	   by	   the	   cell	   or	   can	   be	   constituted	   by	   cellular	   material	  destined	   for	   turn	   over.	   A	   complex	   catabolic	   network	   resides	   in	   the	   lysosome.	  Catalytic	   insufficiency	   on	   any	   one	   of	   the	   many	   enzymes	   involved	   in	   these	  catabolic	   pathways	   will	   result	   in	   accumulation	   of	   that	   enzyme’s	   substrate,	  interruption	   of	   the	  metabolic	   pathway	   and	   indirect	   effects	   on	   other	   pathways.	  Glucocerebrosidase	   catalyses	   the	   breakdown	   of	   glucocerebroside	   into	   glucose	  and	   ceramide,	   and	   mutations	   in	   the	   GBA	   gene	   lead	   to	   Gaucher	   disease,	  characterized	   by	   glucocerebroside	   accumulation.	   The	   phenotype	   is	   essentially	  determined	  by	  the	  combination	  of	  mutations	  on	  both	  alleles,	  but	  environmental	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factors	   may	   also	   play	   a	   role	   in	   the	   severity	   of	   the	   clinical	   presentation.	   GBA	  mutations	  are	  identified	  based	  on	  the	  amino	  acid	  position	  in	  the	  mature	  enzyme,	  with	  Ala40	  designated	  as	  the	  first	  residue	  (G.	  A.	  Grabowski,	  2008;	  Hruska	  et	  al.,	  2008).	  More	  than	  250	  different	  mutations	  in	  the	  GBA	  gene	  have	  been	  described,	  including	  point	  mutations,	  insertions	  and	  deletions	  (G.	  A.	  Grabowski	  et	  al.,	  2011;	  G.	   a	   Grabowski,	   2012;	   Gupta	   et	   al.,	   2011;	   Lieberman,	   2011).	   Recombination	  events	  between	  GBA	  and	   its	  highly	  homologous	  downstream	  pseudo-­‐gene	  have	  produced	  a	  significant	  number	  of	  complex	  mutations;	  these	  can	  be	  the	  result	  of	  gene	   conversion,	   fusion	   or	   duplication.	   The	   250	   mutations	   described	   to	   date	  include	  203	  missense	  mutations,	  18	  nonsense	  mutations,	  36	  small	  insertions	  or	  deletions	   that	   lead	   to	   either	   frameshifts	   or	   in-­‐frame	   alterations,	   14	   splice	  junction	  mutations,	  and	  13	  complex	  alleles	  resulting	  of	  recombination	  with	  GBA	  pseudo-­‐gene.	   Some	   complex	   alleles	   can	   carry	   two	   or	   more	   mutations	   in	   cis.	  (Hruska	  et	  al.,	  2008).	  A	   main	   point	   of	   interest	   in	   characterizing	   mutations	   for	   any	   genetic	  disease	  is	  the	  ability	  to	  predict	  clinical	  prognosis.	  In	  GD,	  we	  find	  a	  broad	  range	  of	  mutations	   causing	   a	  wide	   range	  of	   clinical	  presentations	   and	  a	  poor	   genotype-­‐phenotype	   correlation.	   This	   makes	   it	   difficult	   to	   summarize	   our	   current	  knowledge	  on	  the	  subject;	  however,	  a	  number	  of	  observations	  can	  be	  made:	  	   1.	   The	   most	   prevalent	   mutations	   are	   L444P	   (c1448T>C)	   and	   N370S	  (c.1226A>G).	  	  	   2.	   The	   most	   common	   mutations	   in	   GD	   are:	   N370S,	   84GG,	   L444P	   and	  IVS2+1.	  	  	   3.	   The	   presence	   of	   the	   N370S	   mutation	   in	   one	   or	   both	   alleles	   is	   often	  associated	   to	  GDT1.	  The	  mutation	   is	   considered	  neuroprotective	  as	   individuals	  carrying	  this	  mutation	  rarely	  present	  neurological	  symptoms	  (Figure	  3).	  	   4.	   The	   presence	   of	   the	   mutations	   L444P	   or	   D409H	   is	   frequently	  associated	  to	  the	  development	  of	  neurological	  symptoms	  and	  frequently	  found	  in	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GDT2	   and	   GDT3	   patients	   (Guggenbuhl,	   Grosbois,	   &	   Chalès,	   2008;	   Tsuji	   et	   al.,	  1988)	  (Figure	  3).	  	  5.	  Many	  point	  mutations	  have	  been	  identified	  and	  homozygosity	  for	  those	  mutations	  has	  been	  associated	  with	  all	  types	  of	  GD.	  	   	  	  	  	  	  	  	  	  	  	  	  
Figure	   3	   -­‐	   Classification	   of	   Gaucher	   Disease	   on	   genotype-­‐phenotype.	  Mutation	  N370S	   is	  one	  of	   the	   few	  recognized	  genotype-­‐phenotype	  correlations	  related	  in	  patients	  with	  type	  1	  GD.	  In	  type	  2	  GD	  the	  L444P	  mutation	  is	  frequently	  found,	   however	   the	   recombinant	   and	   rare	   alleles	   are	  particularly	  predominant	  on	  this	  type.	  In	  type	  3	  GD	  patients	  commonly	  carry	  the	  L444P	  mutation	  and,	  as	  well,	  an	  atypical	  phenotype	  is	  related	  with	  mutation	  D409H	  on	  this	  type.	  Adapted	  
from:	  Bohra	  &	  Nair,	  2011;	  Hruska	  et	  al.,	  2008.	  	   	  While	   it	   is	   possible	   to	   identify	   individual	  mutant	   alleles	   in	   GD	   patients,	  this	  capability	  has	  limited	  advantages,	  as	  it	  is	  difficult	  to	  predict	  phenotype	  from	  genotype.	   The	   majority	   GBA	  mutations	   can	   be	   found	   in	   all	   three	   types	   of	   GD	  patients.	  Patients	  who	  share	  the	  same	  genotype	  may	  present	  different	  symptoms,	  clinical	   progress	   and	   responses	   to	   therapy.	   Conversely,	   patients	  with	   the	   same	  genotypes	  can	  show	  marked	  differences	  in	  clinical	  presentation.	  There	  are	  even	  distinct	  differences	  between	  siblings	  and	  twin	  brothers	  with	  the	  same	  genotype	  (Hruska	  et	  al.,	  2008;	  Park	  et	  al.,	  2003).	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1.4.3.2	  Gaucher	  Disease	  in	  specific	  ethnic	  groups	  	  
1.4.3.2.1	  Ashkenazi	  Jews	  population	  	   Ashkenazi	   Jews	  are	   the	  group	  with	   the	  highest	  prevalence	  of	  GD	   (1:855	  live	  births).	  Usually,	  the	  carrier	  frequency	  for	  GBA	  mutations	  amongst	  this	  group	  is	   set	   between	   1	   in	   14	   and	   1	   in	   18.	   The	   most	   frequent	   mutation	   is	   the	   A-­‐>G	  transition	  at	  1226G,	  the	  mutation	  that	  causes	  an	  Asn-­‐>Ser	  substitution	  at	  amino	  acid	  370	  of	  the	  mature	  protein.	  Mutation	  N370S	  accounts	  for	  approximately	  70%	  of	  mutant	   alleles	   (Sidransky,	   2013).	  This	  mutation	   is	   present	   in	   approximately	  6%	  of	  the	  Ashkenazi	  Jews	  population	  and	  is	  the	  main	  cause	  of	  the	  high	  incidence	  of	  Gaucher	  disease	  in	  this	  ethnic	  group.	  The	  second	  most	  frequent	  mutation	  is	  an	  insertion	  of	  a	  guanine	  at	  nt.84	  of	  the	  cDNA	  and	  has	  an	  incidence	  of	  about	  0.6%.	  Among	   this	   population,	   the	   combined	   frequency	   of	   the	   N370S	   and	   c.84dupG	  mutations	  is	  0.0343,	  resulting	  in	  a	  combined	  incidence	  of	  1:855.	  This	  population	  generally	  presents	  type	  1	  disease	  (Sidransky,	  2013).	  	  
1.4.3.2.	  Norrbottinian	  population	  	  In	  the	  Norrbottinian	  population,	  in	  Northern	  Sweeden,	  there	  is	  an	  AT	  à	  C	  transition	   at	   nt.1448,	  which	   produces	   a	   Leu	  à	   Pro	   substitution	   at	   amino	   acid	  444	   of	   the	   mature	   protein.	   It	   has	   a	   moderately	   high	   frequency	   amongst	   this	  population	  even	  though	  it	  is	  revealed	  in	  other	  populations	  at	  lower	  frequencies.	  This	  population	  commonly	  presents	  type	  3	  GD	  (Sidransky,	  2013).	  
	  	  
1.4.3.3.	  Genotype	  analysis	  	  	  A	   number	   of	   PCR	   based	   genotyping	   assays	   are	   available	   for	   the	   most	  frequent	   GD	   mutations,	   but	   the	   identification	   of	   mutant	   GBA	   alleles	   can	   be	  problematic,	  as	  primers	  must	  be	  designed	  to	  discriminate	  between	  the	  functional	  gene	   and	   the	   pseudo-­‐gene	   (Hruska	   et	   al.,	   2008).	   Furthermore,	   detection	   of	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recombinant	   alleles	   can	   pose	   particular	   difficulties.	   Southern	   blot	   can	   help	  resolve	  ambiguities,	  but	  ultimately,	  direct	  sequencing	  is	  being	  increasingly	  used	  to	  characterize	  mutant	  alleles,	  as	   this	   technique	  can	  detect	  structure	  as	  well	  as	  frequent,	  rare	  or	  novel	  mutations	  (Hruska	  et	  al.,	  2008).	  	  
1.4.3.4.	  Inheritance	  patterns	  of	  the	  disease	  	   GD	   inheritance	   is	   autosomal	   recessive.	   Heterozygotes	   are	   generally	  asymptomatic.	   Assuming	   both	   parents	   are	   heterozygotes,	   each	   child	   of	   the	  couple	   has	   a	   25%	   probability	   of	   being	   affected,	   a	   50%	   chance	   of	   being	   an	  asymptomatic	   carrier	   and	   a	   25%	   possibility	   of	   not	   carrying	   a	   GD	   allele	   (G.	   a	  Grabowski,	  2012;	  Pastores	  &	  Hughes,	  2014).	  Prenatal	  diagnosis	  may	  be	  offered	  to	  high-­‐risk	  families	  and	  the	  diagnosis	  consists	  on	  glucocerebrosidase	  assays	  in	  amniotic	   fluid	   cells	   or	   chorionic	   villi.	   Based	   on	   this	   information	   and	   the	  identification	   of	   GBA	   or	   GBAP	   mutations	   in	   family	   members,	   an	   expected	  phenotype	  can	  be	  deduced	  (Guggenbuhl	  et	  al.,	  2008).	  
	  
1.5	  Molecular	  mechanisms	  of	  GD	  
1.5.1	  Sphingolipid	  metabolism	  	   Sphingolipids	   are	   synthesized	   in	   the	   endoplasmic	   reticulum	   from	  nonsphingolipid	   precursors.	   Sphingolipids	   perform	   important	   functions	   in	  membrane	   biology	   and	   therefore	   have	   important	   effects	   on	   cell	   metabolism.	  Although	   there	   is	   a	   great	   diversity	   on	   both	   structure	   and	   function	   of	  sphingolipids,	   all	   of	   them	   share	   a	   common	   anabolic	   and	   catabolic	   pathway	  (Gault,	  Obeid,	  &	  Hannun,	  2011).	  The	  metabolism	  of	  sphingolipids	  can	  be	  viewed	  as	   a	   set	   of	   interconnected	   networks	   that	   diverge	   from	   a	   single	   common	   entry	  point	  and	  flock	  to	  a	  single	  common	  breakdown	  pathway.	  Their	  simplest	  forms	  –	  sphingosine,	  phytosphingosine	  or	  dihydrosphingosine	  –	  serve	  as	  the	  backbone	  of	  more	   complex	   molecules.	   For	   example,	   the	   acylation	   of	   sphingosine,	  phytosphingosine	  or	  dihydrosphingosine	  with	  a	  variety	  of	  acetyl-­‐CoA	  molecules	  by	  the	  action	  of	  various	  ceramide	  synthase	  gives	  rise	  to	  long	  molecules	  such	  as	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ceramide	   or	   phytoceramida	   dihydriceramida	   (Gault	   et	   al.,	   2011).	   A	   particular	  class	  of	  sphingolipids	  are	  the	  glycosphingolipids	  (GSL)	  that	  are	  characterized	  by	  the	  kind	  of	  sugar	  residues	  attached	  to	  their	  ceramide	  headgroup.	  GSL	  are	  broadly	  divided	   into	   two	  categories:	  glycosphingolipids	  and	  galactosphingolipids	   (Gault	  et	  al.,	  2011).	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  Figure	  4	  -­‐	  Glucocerebrosidase	  function.	  Glucosylceramide	  is	  cleaved	  by	  Glucocerebrosidase	  into	  Ceramide	  and	  Glucose,	  in	  the	  normal	  function	  of	  the	   enzyme,	   as	   represented	   in	   the	   red	   square.	   Whereas	  Glucosylsphingosine	   is	   cleaved	   by	   Glucocerebrosidase	   into	   Glucose	   and	  Sphingosine.	   Glucocerebrosidase	   is	   mutated	   in	   GD	   resulting	   in	   the	  accumulation	  of	  Glucosylceramide	  mainly	  in	  the	  lysosomes.	  Adapted	  from:	  Sidransky,	  2013.	  	  	  	  
1.5.2	  Molecular	  mechanisms	  	  	   The	   enzyme	   glucocerebrosidase	   (also	   known	   as	   GBA;	   acid	   beta-­‐glucosidase;	  beta-­‐glucocerebrosidase;	  glucosylhydrolase;	  glucosylceramidase)	  is	  synthesized	   in	   the	  ER	  and	  trafficked	   to	   the	   lysosome.	  While	  on	  route,	   it	   suffers	  post-­‐translational	   modifications,	   mainly	   in	   the	   form	   of	   addition	   of	   mannose	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carbohydrates	  at	  selected	  Asn	  residues.	  Once	  in	  the	  lysosome,	  it	  hydrolyses	  the	  glucocerebroside	   (also	   called	   glucosylceramide)	   to	   glucose	   and	   ceramide,	   as	  shown	   in	   Figure	   4.	   As	   a	   direct	   result	   of	  mutation,	   enzyme	   structure	   is	   altered	  with	  several	  possible	  consequences,	  depending	  on	  the	  nature	  of	  the	  mutation.	  A	  mutation	   in	   the	   active	   site	   of	   the	   enzyme	   will	   affect	   its	   catalytic	   function.	   A	  mutation	   elsewhere	   in	   the	   enzyme	   can	   also	   affect	   catalytic	   activity	   indirectly.	  	  Another	  consequence	  of	  a	  mutation	  can	  be	  a	  modification	  of	  the	  stability	  of	  the	  protein,	  resulting	  in	  increased	  protein	  degradation,	  which	  ultimately	  diminishes	  the	  amount	  of	  active	  enzyme	  reaching	   the	   lysosome.	   	  As	  a	   result,	   the	  enzyme’s	  substrate,	   glucosylceramide	   is	   accumulated.	   In	   monocyte-­‐lineage	   cells,	   these	  lipid-­‐laden	  lysosomes	  result	  into	  the	  characteristic	  “Gaucher	  cells”.	  They	  present	  a	  large	  reticuloendothelial	  system,	  a	  small	  and	  eccentrically	  placed	  nuclei	  and	  a	  striated	   cytoplasm	   as	   shown	   in	   Figure	   5	   (G.	   A.	   Grabowski,	   2008;	   Vairo	   et	   al.,	  2013).	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   5	   -­‐	  Gaucher	   cells	   from	   a	   bone	   marrow	   aspirate.	   These	   cells	  derive	   from	  macrophages	  with	  stored	  glycolipids.	  They	  measure	  around	  20	   –	   100µm	   in	   diameter.	   Gaucher	   cells	   are	   also	   swollen	   and	   have	   a	  cytoplasm	   that	   looks	   lacy.	   Adapted	   from:	   Elstein,	   Abrahamov,	   Hadas-­‐halpern,	  &	  Zimran,	  2001;	  Vairo	  et	  al.,	  2013.	  	  	  
Gaucher	  
cells	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  The	  dysfunctional	  catabolism	  of	  glycosylceramide	  and	  the	  enlargement	  of	  macrophages	  by	  glucocerebrosidase	  substrates	  accumulation	  are	  the	  basis	  of	  the	  visceral	  manifestations	   in	  GD.	   Central	   to	   the	  multisystemic	   presentation	   of	   the	  disease	   is	   the	   fact	   that	  monocytic	  cells	   in	  circulation	  penetrate	  multiple	  organs	  and	   differentiate	   into	  macrophages.	  Mouse	  models	   of	   GD	   have	   shown	   that	   the	  classic	  and	  alternative	  pathways	  of	  macrophage	  activation	  are	  both	  modified	  in	  the	   GD.	   However	   the	   mechanisms	   whereby	   systemic	   and	   organ-­‐specific	  involvement	   are	   initiated	   and	   developed	   remain	   poorly	   understood	   (G.	   A.	  Grabowski,	   2008).	   Another	   process	   that	   may	   result	   from	   abnormal	   folding	   of	  mutant	   proteins	   in	   the	   endoplasmic	   reticulum	   is	   triggering	   of	   apoptotic	   or	  inflammatory	  responses	  in	  several	  tissues.	  Therefore	  the	  development	  of	  agents	  capable	   of	   neutralizing	   the	   unfolded	   protein	   response	   could	   be	   an	   effective	  therapeutic	  strategy	  in	  GD	  (G.	  A.	  Grabowski,	  2008).	  
	  
1.6	  Therapeutic	  Approaches	  
	  
	   In	  any	  disease	  the	  goal	  of	  therapy	  is	  to	  improve	  the	  patients	  quality	  of	  life	  by	   either	  healing	   the	  disorder	   or	  managing	   its	   outcome.	  Numerous	   treatments	  and	   approaches	   are	   in	   use	   or	   under	   development	   for	   GD.	   All	   of	   them	   are	  intended	   to	   reduce	   glucosylceramide	   accumulation	   and	   to	   minimize	   the	  consequences	   of	   its	   storage	   in	   patients.	   Current	   treatments	   only	   address	   the	  systemic	  aspects	  of	  the	  disease	  (Gupta	  et	  al.,	  2011;	  Lieberman,	  2011).	  	  Therapeutic	  Approaches	  to	  GD	  treatment:	  	   -­‐ Enzyme	  replacement	  therapy	  (ERT);	  -­‐ Substrate	  reduction	  therapy	  (SRT);	  -­‐ Bone	  marrow	  transplantation	  (also	  known	  as	  stem	  cell	  transplantation);	  -­‐ Surgical	  (splenectomy).	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1.6.1	  Enzyme	  replacement	  therapy	  	  	   Enzyme	   replacement	   therapy	   (imiglucerase)	   uses	   recombinant	   enzyme	  administered	  intravenously	  to	  provide	  functional	  glucocerebrosidase	  to	  patients.	  The	   first	  GD	  therapy	  used	  was	  based	  on	  an	  alglucerase	  (Ceredase®),	  approved	  by	   FDA	   in	  April	   1991.	   In	  May	   1994	   FDA	   approved	   imiglucerase	   (Cerezyme®),	  which	  replaced	  the	  use	  of	  alglucerase	  (Gupta	  et	  al.,	  2011;	  Lieberman,	  2011).	  	   Infused	   enzyme	   is	   endocytosed	   by	   circulating	   macrophages	   and	  eventually	  reaches	  the	   lysosomal	  compartment	  where	   it	  restores	   function.	  As	  a	  result,	  there	  is	  a	  significant	  decrease	  in	  size	  of	  the	  liver	  and	  spleen,	  a	  reduction	  in	  bone	   abnormalities	   and	   also	   some	   reversion	   in	   other	   typical	   GD	   clinical	  manifestations.	  However	  pulmonary	  symptoms	  respond	  poorly.	  Due	  to	  the	  costs	  of	  recombinant	  enzyme	  production	  and	  the	  relatively	  small	  market,	  this	  therapy	  is	  expensive	   for	  patients	  and	  health	  care	  systems,	  amounting	  to	  over	  200,000€	  per	  patient	  per	  year.	  Other	  drawbacks	  of	  ERT	  therapy	  involve	  the	  inconvenience	  of	   regular	   infusions,	   risk	   of	   side	   effects	   and	   immunological	   rejection	   to	   the	  recombinant	  enzyme	  (Gupta	  et	  al.,	  2011;	  Tiscornia	  et	  al.,	  2013).	  	  
1.6.2	  Substrate	  reduction	  therapy	  	  	   Substrate	   reduction	   therapy	   uses	   a	   small	   molecule	   inhibitor	   of	   the	  glucosylceramide	   biosynthetic	   enzyme.	   The	   main	   goal	   of	   this	   strategy	   is	   to	  inhibit	   synthesis	  of	   glusosylceramide.	   If	   the	   substrate	   is	  not	   synthesized	   in	   the	  first	   place,	   it	   cannot	   accumulate	   if	   glucocerebrosidase	   is	   absent.	   This	   method	  uses	   an	   imino	   sugar	   as	   inhibitor	   (Miglustat®)	   of	   the	   first	   step	   in	   glycolipid	  synthesis.	   Currently	   the	   only	   FDA-­‐approved	   SRT	   agent	   is	   N-­‐	  butyl-­‐deoxynojirimycin	  (NB-­‐DNJ)	  (Miglustat	  or	  Zavesca®),	  which	  is	  mainly	  used	  to	   treat	   GD	   type	   1	   patients.	   However,	   this	   treatment	   is	   also	   expensive	   and	  presents	  adverse	  reactions	  (non	  allergic)	  (Gupta	  et	  al.,	  2011).	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1.6.3	  Bone	  marrow	  transplantation	  (stem	  cell	  transplantation)	  	  	   Bone	  marrow	  transplantation,	  also	  known	  as	  stem	  cell	  transplantation	  is	  one	   alternative	   treatment	   for	   Gaucher	   disease.	   It	   has	   a	   lower	   cost	   and	   the	  patients’	   response	  has	  been	  positive.	  This	   treatment	  has	  been	  used	   to	   treat	  GD	  non-­‐neurological	  manifestations,	  since	  the	  transplanted	  bone	  marrow	  restores	  a	  population	   of	   monocytes	   with	   active	   glucocerebrosidase.	   For	   unclear	   reasons,	  this	   procedure	   seems	   to	   be	   an	   appropriate	   option	   to	   treat	   GD	   type	   3	   patients.	  The	  approach	  still	  has	  significant	  risks	  associated,	  particularly	  a	  10%	  incidence	  of	  mortality	  due	  to	  surgery	  (Gupta	  et	  al.,	  2011).	  	  
1.6.4	  Surgical	  intervention	  	  	   Splenectomy	  (surgery	  to	  remove	  spleen)	  can	  be	  partial	  or	  total	  and	  may	  be	  an	  option	  in	  exceptional	  cases	  if	  the	  organ	  acquires	  dimensions	  that	  affect	  the	  patient’s	  daily	  quality	  of	  life,	  or	  if	  it	  has	  significant	  areas	  of	  infarction.	  In	  certain	  cases,	  as	  when	   the	  patients	  suffer	   from	  severe	   thrombocytopenia,	  present	  high	  risk	  of	  bleeding	  or	  anaemia,	  surgical	  interventions	  are	  not	  recommended.	  Partial	  splenectomy	  can	  achieve	  the	  benefits	  of	  complete	  splenectomy	  and	  reduces	  the	  risk	  of	  infection.	  However,	  re-­‐growth	  of	  the	  splenic	  remnant	  has	  been	  observed,	  along	   with	   the	   re-­‐emergence	   of	   pre-­‐operative	   symptoms	   and	   new	   bone	  involvement	  can	  occur	  after	  most	  of	  partial	  splenectomies	  (Gupta	  et	  al.,	  2011).	  
	  
	  
1.7	  Pharmacological	  Chaperones	  (PCs)	  
1.7.1	  Chaperone	  therapy	  	  
	   It	   remains	   a	   challenge	   to	   find	   a	   therapy	   to	   stop,	   stabilize	   or	   reduce	   the	  neurological	  manifestations	  of	  the	  disease	  in	  GDT2	  and	  GDT3.	  ERT	  has	  no	  effect	  on	   CNS	   symptoms,	   mostly	   due	   to	   the	   inability	   of	   the	   recombinant	   enzyme	   to	  cross	   the	   blood-­‐brain	   barrier.	   The	   response	   to	   SRT	   is	   also	   poor.	   The	  identification	   of	   prenatal	   lethal	   forms	   show	   that	   the	   neurological	   damage	  may	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already	   be	   present	   in	   the	   most	   severe	   forms	   of	   the	   disease,	   adding	   a	   further	  barrier	  to	  the	  therapeutic	  agent	  (Gupta	  et	  al.,	  2011).	  	   In	   recent	   years	   a	   novel	   therapeutic	   approach	   is	   being	   researched	   and	  developed	  in	  GD	  and	  other	  LSD,	  involves	  the	  use	  of	  pharmacological	  chaperones	  (PC),	   or	   enzyme	   enhancement	   therapy	   (EET).	   PCs	   are	   small	   organic	  molecules	  capable	  of	  reversible	  interaction	  with	  glucocerebrosidase	  in	  such	  a	  way	  that	  they	  restore	   the	   original	   3D	   structure	   of	   the	   protein	   or	   otherwise	   stabilize	   its	  conformation.	   The	   use	   of	   PCs	   stabilizes	   the	   native	   conformation	   of	   mutant	  enzymes	  as	  they	  fold	  in	  the	  endoplasmic	  reticulum,	  enabling	  them	  to	  pass	  the	  ER	  quality	   control	   system	   and	   preventing	   the	   ER	   associated	   degradation	   system.	  Therefore	  it	  enables	  their	  trafficking	  from	  the	  endoplasmic	  reticulum	  to	  the	  Golgi	  and	  to	  the	  lysosome.	  Once	  the	  chaperone-­‐enzyme	  complex	  reaches	  the	  lysosome,	  the	  chaperone-­‐enzyme	  complex	  dissociates	  due	  to	  presence	  of	  excess	  substrate.	  Some	   strategies	   for	   synthesis	   attempt	   to	   design	   PCs	   that	   are	   sensitive	   to	   pH,	  having	  high	  affinity	  of	  the	  enzyme	  at	  neutral	  pH	  (as	  is	  found	  in	  the	  ER)	  but	  low	  affinity	  at	  lower	  pH	  (as	  found	  in	  the	  lysosome)	  (Tropak	  et	  al.,	  2008).	  PCs	  represent	  a	  particularly	  promising	  therapeutic	  strategy	  because	  they	  combine	   the	   benefits	   of	   a	   small-­‐molecule	   approach-­‐oral	   bioavailability,	   cell	  permeability	   and	   the	   capacity	   to	   cross	   the	   blood-­‐brain	   barrier	   with	   the	  specificity	  and	  selectivity	  of	  enzyme	  replacement	  therapy.	  These	  small	  molecules	  can	  be	  less	  expensive	  than	  other	  therapies	  such	  as	  ERT	  and	  offer	  the	  possibility	  of	  treating	  the	  neurological	  aspects	  of	  type	  2	  and	  3	  GD	  patients	  (Tiscornia	  et	  al.,	  2013;	   Tropak	   et	   al.,	   2008;	   Yu,	   Sawkar,	   Whalen,	   Wong,	   &	   Kelly,	   2007).	   Recent	  studies	   report	   that	   PCs	   have	   good	   properties	   regarding	   oral	   administration,	  specifically	  enhancing	  glucocerebrosidase	  activity	  in	  mouse	  tissues	  as	  the	  brain	  and	   also	   lacking	   acute	   toxicity	   at	   high	   doses	   in	   normal	   mice.	   It	   is	   generally	  accepted	   that	   even	   small	   increases	   in	   glucocerebrosidase	   activity	   would	   be	  required	  to	  reach	  a	  clinical	  effect,	  therefore	  chaperone	  therapy	  results	  warrants	  further	  development	  (Tiscornia	  et	  al.,	  2013).	  Moreover,	  the	  use	  of	  a	  fluorescent	  labelled	   derivative	   demonstrated	   its	   ability	   to	   cross	   the	   cell	   membrane	   and	  increased	   the	   levels	   of	   glucocerebrosidase	   in	   mature	   and	   also	   immature	  neuronal	  cells	   (Tiscornia	  et	  al.,	  2013).	  Several	  promising	  chaperone	  candidates	  for	  GD	  are	  currently	  in	  in	  phase	  I	  and	  II	  of	  clinical	  trials	  (Gupta	  et	  al.,	  2011).	  
Chapter	  1	  -­‐	  Introduction	  	  
Raquel	  da	  Fonseca	  Gonçalves	   	   	   	  17
	  
1.8	  Objective	  	   The	  main	   goal	   of	   this	   thesis	   is	   to	   test	   8	   different	   novel	   PCs	   in	   terms	   of	  their	   effects	   on	   glucocerebrosidase	   stability	   and	   activity	   in	   fibroblast	   primary	  cultures	   from	   GD	   patients	   with	   4	   different	   genotypes.	   This	   approach	   is	   an	  important	   first	   step	   in	   characterizing	   these	   novel	   pharmacological	   chaperone	  candidates.	   We	   therefore	   set	   out	   to	   establish	   several	   techniques	   needed	   for	  measuring	  protein	  levels	  and	  enzymatic	  activity	  of	  GBA	  in	  our	  laboratory.	  In	  the	  long	   term,	   these	   techniques	   will	   be	   used	   to	   test	   the	   effect	   of	   chaperone	  compounds	  on	  neurons	  derived	  from	  IPSc	  of	  GD	  patients,	  to	  determine	  potential	  uses	  in	  therapy.	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Chapter	  2	   	   	   	  
Materials	  and	  Methods	  	  
2.1	  Cell	  harvest	  and	  protein	  extraction	  	  	   1.	  The	  cells	  were	  washed	  twice	  with	  PBS	  1x	  and	  harvested	  by	  trypsinization	  or	   scrapping.	   Cells	   were	   centrifuged	   for	   5min	   at	   3000rpm	   and	   all	   cell	   pellets	  were	  frozen	  and	  stored	  at	  -­‐20ºC.	  2. RIPA	  buffer	  was	  added	  and	  the	  cell	  pellet	  resuspended.	  	  3. The	  cell	  suspension	  was	  incubated	  on	  ice	  for	  15	  min	  mixing	  every	  3	  min.	  4. The	  lysate	  was	  centrifuged	  at	  13,000	  rpm	  at	  4ºC	  for	  15	  min.	  5. The	  supernatant	  was	  collected,	  aliquoted	  and	  stored	  at	  -­‐20ºC.	  	  For	  reagent	  preparation:	  see	  Annexes.	  
	  
2.2	  Protein	  Concentration	  Assay	  	  Protein	  concentration	  was	  determined	  by	  the	  Bradford	  method:	  	   1. Using	  a	  stock	  solution	  of	  BSA	  (10µg/µl),	  the	  following	  standard	  curve	  was	  prepared	  in	  triplicate:	  	   Final	  concentration	   	  	  	  	  	  	  	  Stock	  solution	  volume	  	  	  	  	  	  	  	  	  	  	  Water	  volume	  used	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  to	  dilute	  stock	  solution	  
BSA	  µg/µl	   µl	  BSA	  10µg/µl	   µl	  H20	  0	   0	   100	  0.2	   2	   98	  0.4	   4	   96	  0.6	   6	   94	  0.8	   8	   92	  1	   10	   90	  	   	   	   	   	   	   	   	  	  2. 1	  µl	  of	  each	  standard	  was	  added	  to	  99	  µl	  of	  Bradford	  reagent.	  	  3. Samples	   were	   diluted	   between	   1/1	   and	   1/100,	   as	   required,	   until	   the	  reading	  fell	  into	  the	  linear	  range	  of	  the	  standard	  curve.	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   4. Absorbance	   at	   595nm	   was	   determined	   and	   plotted	   against	   BSA	  concentration.	   The	   slope	   of	   the	   line	   (m)	   was	   calculated.	   To	   calculate	  protein	   concentration,	   the	   absorbance	   at	   595nm	   for	   each	   sample	   was	  divided	   by	   m	   and	   multiplied	   by	   the	   dilution	   factor,	   giving	   protein	  concentration	  in	  µg/µl.	  
	  Preparation	  of	  reagents:	  see	  Annexes.	  
	  
2.3	  Glucocerebrosidase	  Enzymatic	  Activity	  Assay	  	  	   1. Protein	  extracts	  were	  thawed	  on	  ice;	  	   2. Using	   a	   stock	   solution	   of	   4-­‐methyl-­‐umbelliferone	   (SIGMA®	   M1381)	  (1.42nmol/µl),	   a	   standard	  curve	  was	  prepared	   in	   triplicate	  according	   to	  the	  following	  table:	  	  
	  	   3. 200µl	  of	  Glycine	  buffer	  were	  added.	  	  4. Samples	  were	  subjected	  to	  fluorometry	  by	  exciting	  at	  366nm	  and	  reading	  absorbance	  at	  446nm.	  Emission	  was	  plotted	  against	  nmol	  of	  4MU	  and	  the	  slope	  of	  the	  line	  (m)	  determined.	  	  
Stock	  solution	  	  





µl	  0	   µl	  20	   nmol	  0	  1	   19	   1.42	  2	   18	   2.84	  5	   15	   7.19	  10	   10	   14.2	  15	   5	   21.3	  20	   0	   28.4	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5. For	   each	   sample,	   dilutions	   were	   made	   between	   1/1	   and	   1/100,	   as	  necessary,	   until	   the	   reading	   fell	   into	   the	   linear	   range	   of	   the	   standard	  curve.	  	   6. 10µl	   of	   PE	   for	   each	   sample	   (in	   triplicate)	   were	   mixed	   with	   20µl	   of	  Substrate	   Solution	   and	   incubated	   at	   37ºC	   for	   1	   hour.	   Reaction	   was	  stopped	  by	  addition	  of	  200µl	  of	  Glycine	  Buffer.	  	   7. Samples	  were	  subjected	  to	  fluorometry	  by	  exciting	  at	  366nm	  and	  reading	  emission	   at	   446	   nm.	   Emission	   (light	   units)	  was	   plotted	   against	   nmol	   of	  4MU.	  	   8. The	  light	  unit	  value	  for	  the	  sample	  was	  divided	  by	  (m)	  to	  obtain	  nmol	  of	  MU	  produced	  by	  GBA	  present	  in	  the	  10µl	  of	  sample	  tested.	  This	  value	  was	  normalized	  to	  total	  protein	  in	  the	  sample	  tested	  and	  expressed	  as	  nmol	  of	  4MU/µg	  protein/	  hour.	  	  
2.4	  Protein	  Expression	  
2.4.1	  Western	  Blot:	  	   1. A	   10%	   resolving	   gel	   of	   polyacrylamide/	   bis	   acrylamide	   29:1	   and	  stacking	  gel	  were	  prepared;	  2. 10-­‐100	  µg	  of	  PE	  were	  loaded	  per	  lane;	  3. The	  gel	  was	  run	  at	  130V	  for	  1	  hour;	  4. Resolved	  proteins	  were	  transfered	  onto	  a	  PVDF	  membrane	  at	  20V	  for	  1	  hour;	  5. Membrane	  was	  incubated	  in	  blocking	  buffer	  for	  1	  hour;	  6. Membrane	  was	  incubated	  in	  primary	  antibody,	  overnight	  at	  4ºC;	  7. Membrane	   was	   washed	   3	   times	   in	   TBST	   (1x)	   and	   incubated	   in	  secondary	  antibody	  for	  1	  hour	  at	  room	  temperature;	  8. Membrane	  was	  washed	  3	  times	  in	  TBST	  (1x);	  9. Membrane	  was	  developed	  with	  5ml	  ECL	  reagent.	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  Preparation	  of	  reagents	  and	  buffers:	  see	  Annexes.	  
	  
2.4.2	  Antibodies	  used	  in	  this	  study:	  	  
AntiGBA:	   Mouse	   monoclonal	   to	   GBA	   1x100	   ug;	   abcam®discovermore;	   Ref.:	  798203747835;	   Product:	   ab55080;	   Dilution:	   6ul	   AB	   in	   6ml	   BSA	   blocking	  solution.	  	  	  	  	  	  Goat	   anti-­‐mouse	   IgG	   peroxidase-­‐conjugated	   0,8	   mg/ml;	   Affinipure®;	  115-­‐035-­‐003;	  Dilution:	  1ul	  AB	  in	  10ml	  BSA	  blocking	  solution.	  	  
AntiActin:	   Actin	   (I-­‐19):	   sc-­‐1616	   -­‐	   Actin	   goat	   polyclonal;	   Santa	   Cruz	  Biotechnology,	   Inc®;	   starting	   dilution	   1:200,	   dilution	   range	   1:100	   -­‐	   1:1000;	  diluted	  in	  BSA	  blocking	  solution.	  	  	  	  	  	  	  	  	  Goat	  anti	  mouse	  IgG-­‐HRP:	  sc-­‐2005;	  Santa	  Cruz	  Biotechnology,	  Inc	  ®;	  dilution:	  1:5000;	  diluted	  in	  BSA	  blocking	  solution.	  
	  
2.5	  Chaperone	  treatment	  	  Chaperones	  	  	  	  	   	   	  The	  pharmacological	  chaperones	  were	  synthesized	  and	  characterized	  by	  a	   collaborator	   group,	   who	   provided	   them	   number	   coded	   as	   stock	   solutions.	  Chaperones	  were	  labelled	  from	  1	  to	  8.	  	   	   	  WT	  and	  GD	  fibroblasts	  cultured	  in	  DMEM	  +	  10%	  FBS	  at	  37ºC.	  If	  required	  cells	   were	   cultured	   in	   the	   presence	   of	   different	   concentrations	   of	  pharmacological	  chaperones	  and	  the	  medium	  was	  changed	  every	  48hs.	  Typically	  cultures	  were	  exposed	  to	  chaperone	  treatment	  for	  6	  days	  before	  harvesting	  cells	  for	  analysis.	  	  	  Cell	  lines	  used	  in	  this	  study:	  	  WT1:	  an	  immortalized	  human	  fibroblast	  cell	  line.	  WT2:	  a	  primary	  cell	  line	  from	  a	  human	  foreskin	  dissection.	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Fibroblasts	   from	   GD	   patients	   were	   received	   from	   a	   collaborator	   group	  and	   had	   the	   following	   genotypes,	   passage	   and	   patient	   age.	   All	   patients	   were	  diagnosed	  as	  GD	  type	  2	  (GDT2).	  	  	  	  
	  Name	  	   	  	   Genotype	  	   	  	  	  	  	  	  	  	  	  	  	  	  Passage	   	  	  	  	  	  	  	  	  	  	  	  Patient	  age	  GD1	   N188S/	  G193W	   P2	   30	  Years	  GD2	   F213I/	  RecNaI	   P1	   3	  Years	  GD3	   L444P/	  L444P	   P1	   9	  Years	  GD4	   L444P/	  R120W	   P1	   1	  Month	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Chapter	  3	  
Results	  and	  Discussion	  
	  
3.1	  Initial	  characterization	  of	  cell	  lines	  used	  in	  this	  study:	  	  	   The	   fibroblast	   populations	   used	   in	   this	   study	   consisted	   of	   4	   primary	  cultures	   from	   4	   patients	   diagnosed	   with	   GDT2	   with	   4	   different	   genotypes.	   In	  order	  to	  make	  an	  initial	  characterization	  of	  these	  GD	  fibroblast	  populations,	  we	  proceeded	   to	   determine	   the	   levels	   of	   GBA	   protein	   and	   activity	   in	   comparison	  with	  two	  control	  fibroblast	  populations	  by	  Western	  Blot	  (WB)	  and	  fluorometry.	  Two	  fibroblast	  populations	  that	  were	  wild	  type	  (WT)	  in	  terms	  of	  GD	  mutations	  were	  used	  as	  negative	  controls	  (WT1	  and	  WT2).	  More	  details	  and	  characteristics	  on	   these	   cell	   lines	   can	   be	   found	   in	   the	   section	   Materials	   and	   Methods.	   This	  experiment	  also	  had	  the	  goal	  of	  setting	  up	  the	  protocols	  to	  be	  used	  in	  both	  WB	  and	   GBA	   fluorometry	   assays,	   which	   had	   not	   been	   previously	   done	   in	   our	  laboratory.	  	  	  
3.2	  Characterization	  of	  Glucocerebrosidase	  activity	  in	  the	  cell	  lines	  used	  in	  
this	  study.	  	   In	  order	   to	  measure	  glucocerebrosidase	  activity,	   it	  was	   firstly	  necessary	  to	  determine	  the	  protein	  concentration	  of	  the	  samples.	  	  	  
3.2.1	  Bradford	  Assay:	  
	   Cells	  were	  cultured,	  harvested	  and	  protein	  extracts	  made	  as	  indicated	  in	  Materials	   and	   Methods.	   We	   then	   determined	   protein	   concentration	   using	   the	  Bradford	  method.	   This	  method	   is	   a	   colorimetric	   assay	   based	   on	   a	   colour	   shift	  that	   occurs	   when	   the	   dye	   Coomasie	   Brilliant	   Blue	   (brown)	   binds	   to	   proteins	  forming	  a	  complex	  (blue)	  that	  can	  be	  quantified	  by	  measuring	  absorbance	  at	  595	  nm.	  When	   the	   Bradford	   reagent	   is	   added	   to	   a	   solution	   containing	   protein,	   the	  protein-­‐dye	   complex	   forms	   and	   the	   intensity	   of	   the	   blue	   colour	   will	   be	  
Chapter	  3	  –	  Results	  and	  Discussion	  	  
Raquel	  da	  Fonseca	  Gonçalves	   	   	   	  24
proportional	   to	   the	   concentration	   of	   protein.	   In	   order	   to	   correlate	   colour	  intensity	  with	  the	  amount	  of	  protein,	  a	  standard	  curve	  is	  created.	  Using	  a	  protein	  solution	  of	  known	  concentration,	  a	   serial	  dilution	   is	  made,	  aliquots	  mixed	  with	  the	  Bradford	  reagent,	  and	  absorbance	  at	  595	  nm	  measured.	  When	  absorbance	  is	  plotted	   against	   protein	   concentration,	   absorbance	   increases	   in	   a	   linear	  way	   as	  protein	   concentration	   increases,	   until	   absorbance	   reaches	   a	   plateau	   of	  saturation,	   after	  which	   presence	   of	   higher	   amounts	   of	   protein	   do	   not	   result	   in	  increased	   absorbance.	   The	   linear	   range	   of	   the	   curve	   is	   used	   to	   determine	   the	  protein	   concentration	   in	   unknown	   protein	   samples.	   	   The	   standard	   curve	   is	  shown	  in	  Figure	  6.	  	  
	  
Figure	   6	   -­‐	   BSA	   absorbance	   standard	   curve	   determined	   by	  
spectrophotometry.	   Panel	   1:	   Table	   showing	   concentration	   of	   BSA	   used	  [BSA](µg/µl)	   and	   the	   corresponding	  mean	   595nm	   absorbance	   values	   for	   each	  dilution;	   Panel	   2:	   resulting	   standard	   curve;	   	   four	   different	   BSA	   concentrations	  were	   used	   to	   determine	   the	   standard	   curve,	   with	   technical	   triplicates	   were	  performed	  for	  each	  point.	  	  	   	  We	   then	   proceeded	   to	   determine	   protein	   concentration	   in	   our	  WT	   and	  GD	  cell	  lysates	  (Figure	  7).	  To	  do	  so,	  we	  performed	  the	  Bradford	  assay	  on	  aliquots	  of	   our	  protein	   extracts.	  We	   found	   that	   the	   concentration	  of	  protein	   in	   samples	  WT1	  and	  WT2	  was	  higher	  than	  that	  of	  the	  GD	  samples;	  therefore	  we	  diluted	  the	  WT	   samples	   1/5	   and	   1/10	   in	   order	   to	   obtain	   595nm	   readings	   that	  would	   fall	  within	  the	  linear	  range	  of	  the	  standard	  curve.	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Figure	   7	   -­‐	   Absorbance	   of	   protein	   extracts	   of	   WT	   and	   GD	   protein	  
extract	   samples.	   Undiluted	   or	   diluted	   samples	   were	   measured	   for	  absorbance	  at	  595nm	  by	  spectrophotometry.	  
	  	  	   Using	  the	  absorbance	  values,	  we	  calculated	  the	  protein	  concentration	  of	  the	  WT	  and	  GD	  protein	  samples.	  Results	  are	  shown	  in	  Figure	  8.	  	  	  
	  	   	  
Figure	   8	   -­‐	  Protein	   extract	   concentration	   from	  WT	   and	   GD	   patients.	  Using	  	  	  	  	  	  	  the	  values	  of	   absorbance	  at	  595nm	  obtained	  and	   the	  Bradford	   standard	   curve,	  protein	  concentration	  was	  calculated	  in	  µg/µl	  (taking	  into	  account	  dilution)	  for	  each	  sample.	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3.2.2	  Glucocerebrosidase	  Assay:	  	  	  In	  order	  to	  quantify	  the	  amount	  of	  glucocerebrosidase	  present	  in	  a	  given	  sample,	  aliquots	  of	  the	  protein	  extracts	  from	  the	  samples	  were	  mixed	  with	  non-­‐fluorescent	   substrate	   of	   glucocerebrosidase	   called	   4-­‐methylumbelliferyl-­‐B-­‐D-­‐galactoside	  (4-­‐MU-­‐gal).	  Glucocerebosidase	  catalyzes	  the	  degradation	  of	  substrate	  into	   the	   fluorescent	   product	   4-­‐methylumbelliferone	   (4-­‐MU),	   as	   represented	   in	  Figure	  9.	  	  	  	  	  	  
	  
Figure	   9	   -­‐	   GBA	   enzymatic	   activity	   assay	   scheme.	  GBA	  (Glucocerebrosidase)	  catalyzes	  the	  degradation	  of	  the	  non	  fluorescent	  substrate	  4-­‐methylumbelliferyl-­‐B-­‐D-­‐galactoside	  into	  the	  fluorescent	  product	  4methylumbelliferone.	  	  	  	  	   The	  resulting	  product,	  4-­‐methylumbelliferone	  (4MU)	  can	  be	  quantified	  by	  fluorescence	   by	   exciting	   at	   366nm	   and	   measuring	   light	   units	   of	   emission	   at	  446nm.	   Aliquots	   of	   protein	   extracts	   were	   mixed	   with	   4-­‐MU-­‐gal	   substrate	  solution,	   incubated	   for	  1	  hour	  and	   the	   reaction	  slopped	  by	   lowering	   the	  pH	  by	  addition	  of	  excess	  volume	  of	  Glycine	  buffer	  (pH	  =	  2).	  The	  quantity	  of	  light	  units	  can	   therefore	   measure	   the	   fluorescent	   product	   resulting	   from	   the	   reaction	  catalysed	   by	   glucocerebrosidase	   and	   once	   the	   substrate	   is	   in	   excess,	   the	  fluorescence	  will	  be	  proportional	  to	  the	  amount	  of	  active	  enzyme	  present	  in	  the	  protein	  extracts.	  In	  order	  to	  correlate	  light	  units	  measured	  with	  the	  amount	  of	  4-­‐MU	  obtained,	  we	  created	  a	  standard	  curve	  shown	  in	  Figure	  10	  panel	  2.	  Using	  a	  4-­‐MU	   solution	   of	   known	   concentration,	   a	   serial	   dilution	   was	   made	   to	   create	  aliquots	  with	  known	  amounts	  of	  4-­‐MU,	  excited	  at	  366nm	  and	  emission	  at	  446	  nm	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Figure	   10	   -­‐	   4MU	   (4	   methylumbelliferone)	   fluorescence	   standard	   curve	  
determined	  by	  fluorometry.	  Panel	  1:	  4MU	  (nmol)	  and	  the	  corresponding	  mean	  light	   unit	   values.	   Panel	   2:	   4-­‐MU	   standard	   curve	   (six	   different	   amounts	   of	   4MU	  (nmol)	  were	  used	  to	  determine	  the	  standard	  curve	  and	  technical	  triplicates	  were	  performed	   for	  each	  point)	  The	  Y	  axis	   corresponds	   to	   light	  units	  and	   the	  X	  axis	  corresponds	  to	  nmol	  of	  4-­‐MU.	  	  	   We	  then	  proceeded	  to	  perform	  the	  glucocerebrosidase	  assay	  on	  10	  µl	  of	  our	  WT	  and	  GD	  protein	  samples.	  Since	  the	  protein	  extract	  of	  sample	  WT1	  had	  a	  high	   concentration,	   there	  was	   a	   need	   to	   dilute	   the	   sample	  10	   times	   to	   bring	   it	  into	  the	  linear	  range	  of	  the	  standard	  curve.	  Using	  the	  standard	  curve	  presented	  in	  Figure	  10	  panel	  2,	  we	  determined	  the	  nmol	  of	  4-­‐MU	  present	  in	  a	  10	  µl	  aliquot	  of	  each	  of	  our	  protein	  extracts	  (Figure	  11).	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Figure	  11	  -­‐	  Glucocerebrosidase	  assay	  on	  protein	  extracts	  of	  WT	  and	  
GD	  patient	  samples.	  10	  µl	  aliquots	  of	  protein	  extracts	  from	  WT	  and	  GD	  patient	   fibroblasts	   were	   assayed	   and	   light	   units	   (LU)	   determined	   by	  exciting	  at	  366nm	  and	  measuring	  emission	  at	  446nm.	  	  The	  standard	  curve	  was	  used	  to	  determine	  the	  amount	  of	  4-­‐MU	  present	  in	  the	  aliquot	  of	  each	  sample.	  	  	   After	  having	  determined	  a)	   the	  amount	  of	  4-­‐MU	  present	   in	  each	  sample	  and	   b)	   the	   concentration	   of	   total	   protein	   in	   the	   extracts	   of	   each	   sample,	   we	  proceeded	   to	   calculate	   the	   corresponding	   glucocerebrosidase	   activity	   in	   each	  sample.	  With	  the	  amount	  of	  4-­‐MU	  produced	  by	  each	  extract	  in	  1	  hour	  of	  reaction,	  expressed	   in	   relation	   to	   unit	   of	   protein,	   we	   could	   obtain	   a	   measure	   of	  glucocerebrosidase	   activity	   expressed	   as	   nmol	   of	   4-­‐MU/hr/mg	   of	   total	   protein	  (Figure	  12,	  Panel	  1).	  These	  values	  are	  shown	  as	  a	  histogram	  (Figure	  12,	  Panel	  2).	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Figure	   12	   -­‐	   Glucocerebrosidase	   activity	   expressed	   as	   nmol	   4-­‐MU/hr/mg	  
total	  protein.	  Panel1:	  GBA	  activity	  of	  WT	  and	  GD	  samples.	  Panel	  2:	  values	  shown	  in	  a	  histogram	  chart.	  	  	  	   Due	   to	   the	   fact	  of	  being	  a	  preliminary	  experiment	  and	   there	   is	   a	   lack	  of	  technical	  replicates	  on	  this	  GBA	  activity	  assay	  we	  are	  not	  able	  to	  show	  error	  bars.	  Also,	  the	  level	  of	  GBA	  activity	  obtained	  for	  sample	  WT2	  is	  different	  from	  what	  we	  were	  expecting.	  Results	  in	  the	  literature	  indicate	  the	  level	  of	  GBA	  activity	  in	  GD	  samples	  can	  vary,	  depending	  on	   tissue	  or	  cell	   type	  and	  on	  genotype.	  Generally,	  GBA	  activity	  can	  range	  approximately	  between	  1%	  and	  20%	  of	  the	  levels	  found	  in	  WT	  samples.	  Therefore,	  the	  results	  shown	  in	  Figure	  12,	  Panel	  2	  are	  in	  line	  with	  what	   we	   expected,	   with	   the	   exception	   of	   sample	   WT2,	   which	   for	   unknown	  reasons	   seemed	   to	   have	   a	   significantly	   lower	   GBA	   activity	   than	   would	   be	  expected	   for	   a	   WT	   cell	   line.	   WT2	   fibroblasts	   were	   obtained	   from	   a	   foreskin	  biopsy	  of	  a	  healthy	  person.	  One	  possible	  explanation	  for	  the	  low	  GBA	  level	  of	  this	  person	  is	  that	  he	  might	  be	  an	  undetected	  carrier	  of	  a	  mutated	  GBA	  allele.	  If	  this	  were	  the	  case,	  he	  would	  not	  show	  signs	  of	  disease	  and	  his	  GBA	  levels	  would	  be	  expected	  to	  be	  50%	  of	  those	  found	  in	  a	  person	  with	  no	  mutations	  in	  GBA.	  Testing	  for	   this	  hypothesis	  would	  require	   testing	   for	  common	  GD	  mutations	  by	  PCR	  or	  sequencing	  the	  GBA	  gene.	  We	  did	  not	  pursue	  this	  course	  of	  action.	  If	  sample	  WT2	  is	  considered	  ‘anomalous’	  and	  only	  WT1	  is	  taken	  into	  further	  analysis,	  the	  results	  are	  what	  we	  expected:	  high	  level	  of	  activity	  in	  WT1	  and	  uniformly	  low	  levels	  of	  activity	  in	  all	  4	  GD	  samples.	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   In	  order	  to	  extend	  our	  characterization,	  we	  proceeded	  to	  determine	  the	  levels	  of	  glucocerebrosidase	  protein	  in	  our	  samples	  by	  Western	  Blot	  analysis.	  
	  












	  	  	  
Figure	   13	   -­‐	  Western	   Blot	   of	  WT	   and	   GD	   protein	   samples.	   	   Samples	  were	   loaded	   on	   a	   10%	  polyacrylamide	   bis	   acrylamide	   gel	   (30	  µg/lane),	  electrophoresed,	   and	   transferred	   to	   a	   PVDF	   membrane.	   Blocking	   was	  done	   in	   5%	   BSA	   for	   1	   hr	   at	   RT.	   GBA:	   Primary	   antibody	   was	   AntiGBA	  (Affinipure	   ®)	   diluted	   in	   blocking	   solution	   overnight	   at	   4ºC.	   After	  washing,	   secondary	   antibody	   was	   AntiGBA	   (abcam®discovermore)	  diluted	   in	  blocking	   solution	   for	  1	  hr	  at	  RT.	  Actin:	  Primary	  antibody	  was	  AntiActin	   (SC-­‐1616	   Santa	   Cruz	   Biotechnology®)	   diluted	   in	   blocking	  solution	   overnight	   at	   4ºC.	   After	   washing,	   secondary	   antibody	   was	  AntiActin	   (SC-­‐2005	   Santa	   Cruz	   Biotechnology®)	   diluted	   in	   blocking	  solution	  for	  1	  hr	  at	  RT.	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   The	  results	  shown	  in	  Figure	  13	  are	  consistent	  with	  those	  corresponding	  to	  glucocerebrosidase	  activity	  shown	  in	  Figure	  12.	   	  Actin	  levels	  indicate	  that	  all	  lanes	  contained	  similar	  amounts	  of	  protein.	  The	  relatively	  weak	  signal	  observed	  for	   GBA	   in	   WT2	   on	   the	   western	   blot,	   is	   consistent	   with	   the	   low	   GBA	   activity	  observed	   in	   the	   GBA	   activity	   assay,	   suggesting	   indeed	   that	   the	   low	   enzymatic	  activity	   is	  a	   result	  of	   low	  glucocerebrosidase	  concentration	   in	   that	  sample.	  The	  strong	  consistence	  between	  the	  results	  of	  the	  GBA	  activity	  assay	  and	  the	  western	  blot	  analysis	  reinforces	  the	  conclusion	  that	  the	  cell	  lines	  used	  in	  this	  study,	  with	  the	  exception	  of	  WT2,	  behave	  as	  expected	  in	  terms	  of	  glucocerebrosidase	  levels	  and	  activity.	  	  
3.3	  Effect	  of	  chaperone	  compounds	  on	  glucocerebrosidse	  activity	  levels	  in	  
fibroblasts	  from	  4	  GD	  patients	  with	  different	  phenotypes:	  
	   As	  described	  above,	  we	  were	  able	  to	  establish	  GBA	  fluorometric	  assays	  in	  our	  laboratory.	  Before	  proceeding	  to	  the	  actual	  experimental	  measurements	  that	  we	  proposed	  to	  do,	  we	  ran	  the	  GBA	  fluorometric	  assay	  several	  times	  on	  only	  one	  GD	  line	  treated	  with	  only	  one	  chaperone	  compound	  in	  order	  to	  fine-­‐tune	  some	  of	  the	  experimental	  details.	  It	  was	  of	  extreme	  importance	  to	  optimize	  that	  technique	  in	  order	   to	   obtain	   accurate	  measurements.	   In	   particular,	  we	  wanted	   results	   from	  different	   experiments	   to	   be	   comparable,	   so	   it	   was	   important	   to	   establish	   a	  standardized	   procedure	   for	   the	   assay	   and	   particularly	   to	   process	   the	   resulting	  data.	  By	  trial	  and	  error,	  we	  developed	  a	  detailed	  step-­‐by-­‐step	  protocol	  for	  assay	  and	  data	  treatment:	  	   1) Typically,	  an	  experiment	  would	  involve	  a	  chosen	  GD	  fibroblast	  line.	  Cells	  would	   be	   plated	   and	   treated	   with	   different	   concentrations	   of	   a	   given	  chaperone	   compound.	   Cells	   cultured	   in	   absence	   of	   the	   chaperone	  constituted	  the	  negative	  control.	  2) Cell	   cultures	   were	   observed	   and	   any	   toxicity	   effects	   caused	   by	   the	  chaperone	  treatment	  noted.	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3) Protein	   extracts	   were	   made	   and	   protein	   concentration	   determined	   by	  Bradford	  assay	  as	  described	  in	  Materials	  and	  Methods.	  4) For	  the	  GBA	  flurometric	  assay,	  each	  sample	  was	  tested	  in	  triplicate.	  5) Each	   96	   well	   plate	   included	   3	   wells	   with	   all	   reagents	   except	   protein	  extracts	  (background	  fluorescence	  control).	  6) Each	  96	  well	  plate	  included	  a	  GBA	  assay	  standard	  curve.	  Each	  point	  of	  the	  curve	  was	  measured	  in	  triplicate.	  7) Once	   reading	  was	   performed,	   fluorescence	   values	   (light	   units)	   for	   each	  triplicate	   reading	   were	   examined	   and	   values	   that	   are	   obviously	   wrong	  (i.e.,	  more	  that	  2	  standard	  deviations	  from	  the	  mean)	  eliminated	  from	  the	  analysis.	  8) The	   average	   of	   the	   3	   readings	   of	   background	   fluorescence	   were	  calculated.	  	  9) The	   value	   of	   background	   fluorescence	   was	   substracted	   from	   every	  individual	  measurement.	  	  10) The	  triplicate	  measurements	   for	  every	  point	  of	   the	  standard	  curve	  were	  averaged,	   the	   standard	   curve	   plotted	   and	   the	   slope	   of	   the	   curve	   (m)	  calculated.	  	  11) For	  each	  measurement,	  GBA	  activity	  was	  calculated	  (µg	  4MU/hr).	  12) 	  Each	   activity	   value	   was	   normalized	   to	   total	   amount	   of	   protein	   (µg	   4-­‐MU/hr/mg).	  13) 	  Average	  GBA	  activity	  values	  and	  standard	  deviations	  for	  each	  treatment	  were	  calculated	  and	  plotted	  as	  a	  histogram,	  with	  the	  activity	   level	  of	  the	  control	  (no	  chaperone	  treatment	  set	  to	  an	  arbitrary	  value	  of	  100).	  	  	   Once	  this	  procedure	  was	  established,	  we	  began	  measuring	  the	  effect	  of	  each	  chaperone	  on	  each	  of	  the	  GD	  lines.	  	  To	  do	  so,	  for	  each	  of	  the	  GD	  lines	  (GD1,	  GD2,	  GD3	  and	  GD4),	  cultures	  were	  seeded	  and	  cultured	  for	  6	  days	  with	  each	  of	  the	  8	  chaperone	  compounds	  (1,	  2,	  3,	  4,	  5,	  6,	  7	  and	  8)	  at	  concentrations	  of	  0,	  5,	  15,	  30	  and	  50	  µM.	  Media	  was	  changed	  every	  2	  days.	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3.3.1	  Effect	  of	  8	  chaperone	  compounds	  on	  GD1	  fibroblasts	  (GDT2	  genotype	  
N188S/G193W):	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Figure	  14	  -­‐	  Bradford	  Assay	  on	  GD1	  fibroblasts	  treated	  with	  different	  
chaperones.	   Panel	   1:	   Table	   showing	   concentration	   of	   BSA	   used	  [BSA](µg/µl)	  and	  the	  corresponding	  mean	  595nm	  absorbance	  values	  for	  each	   dilution;	   Panel	   2:	   resulting	   standard	   curve;	   four	   different	   BSA	  concentrations	  were	  used	  to	  determine	  the	  standard	  curve,	  with	  technical	  triplicates	   were	   performed	   for	   each	   point.	   Panel	   3:	   Using	   the	   values	   of	  absorbance	  at	  595nm	  obtained	  and	  the	  Bradford	  standard	  curve,	  protein	  concentration	  was	   calculated	   in	  µg/µl	   (taking	   into	   account	   dilution)	   for	  each	  sample.	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Figure	   15	   -­‐	   GBA	   fluorometric	   assay	   of	   GD1	   samples	   and	   GBA	  
standard	  curve.	  Panel	  1:	  GBA	  standard	  curve	  data	  measured	  in	  triplicate.	  Anomalous	  readings	  were	  eliminated	  and	  are	  represented	  by	  ‘X’.	  Panel	  2:	  Standard	   curve	   plot.	   Panel	   3:	   GBA	   assay	   fluorescence	   data	   measure	   in	  triplicate	  (with	  background	  fluorescence	  already	  subtracted).	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  Panel	  1:	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Figure	  16	  -­‐	  Effect	  of	  chaperones	  1-­‐8	  on	  glucocerebrosidase	  activity	  of	  
fibroblasts	   	  (GD1)	  derived	  from	  a	  patient	  with	  GDT2	  with	  genotype	  
N188S/G193W.	  Panel	  1:	  Table	  presenting	  average	  GBA	  assay	  values	  per	  treatment	  along	  with	  standard	  deviations	  (with	  GBA	  value	  for	  untreated	  cells	  set	  to	  an	  arbitrary	  value	  of	  100%).	  Each	  colour	  is	  representative	  of	  the	  number	  of	  chaperone.	  Panel	  2:	  Results	  presented	  as	  histogram	  chart.	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Overall,	  our	  results	  show	  that	  7	  out	  of	  8	  chaperones	  (excluding	  #	  4)	  result	  in	   increased	   glucocerebrosidase	   activities.	   Increases	   range	   from	   0,5	   –	   6	   fold	  compared	   to	   glucocerebrosidase	   activity	   in	   untreated	   cells.	   For	   several	   of	   the	  chaperones,	  increases	  in	  GBA	  activity	  were	  proportional	  to	  the	  concentration	  of	  chaperone	   compound	   (#1,	   2	   and	   5),	   while	   in	   others	   (#3,	   5,	   7	   and	   8)	   all	  concentrations	  tested	  seemed	  to	  increase	  GBA	  activity	  to	  similar	  levels.	  For	  these	  compounds,	   repeating	   the	  analysis	  with	  a	   lower	   range	  of	   concentrations	  might	  reveal	  the	  dosage	  sensitive	  concentration	  range.	  Compound	  #4	  did	  not	  seem	  to	  increase	   activity,	   except	   at	   50µM	   concentration,	   where	   increase	   was	  approximately	  0,6	  fold.	  	  	   We	  then	  wondered	  whether	  the	  increase	  in	  levels	  of	  GBA	  activity	  revealed	  by	   the	   fluorometric	   assay	   would	   be	   reflected	   in	   protein	   levels	   as	   measure	   by	  Western	  blot.	  We	   therefore	   ran	  our	  protein	   extract	   samples	   (30	  µg/lane)	   on	   a	  polyacrylamide	   gel,	   transferred	   the	   resolved	   proteins	   onto	   a	   PVDF	  membrane	  and	   probed	   it	   with	   antibodies	   against	   GBA	   and	   against	   Actin,	   as	   described	   in	  Materials	  and	  Methods.	  Results	  are	  presented	  in	  Figure	  17.	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Figure	   17	   -­‐	   Western	   Blot	   analysis	   of	   GD1	   fibroblasts	   treated	   with	  
increasing	  concentrations	  (0,	  5,	  30	  and	  50µM)	  of	  chaperones	  1-­‐8.	  Panel	  1:	   Effect	   of	   chaperones	   #	   1-­‐4.	   Panel	   2:	   Effect	   of	   chaperones	   #	   5-­‐8.	  Experimental	  details	  are	  described	  in	  Materials	  and	  Methods.	  
	  	  	   Based	   on	   the	   GD1	   GBA	   activity	   assay	   we	   performed	   a	  Western	   Blot	   to	  confirm	  protein	   levels,	   as	   can	  be	  seen	   in	  Figure	  17.	  We	   then	  obtained	   levels	  of	  protein	   expression	   by	   fluorescence	   quantification	   as	   seen	   on	   histograms	   in	  Figure	  17	  panel	  1	  and	  panel	  2,	  showing	  the	  adjusted	  volume	  of	  GD1	  samples.	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Chaperone	   #1	   has	   an	   intense	   protein	   expression	   as	   Western	   Blot	   and	  histogram	  shows,	  according	  to	  GD1	  GBA	  activity	  assay.	  	  Chaperone	  #2	  presents	  a	  certain	   protein	   expression,	   in	   30µM	   and	   50µM	   concentrations	   has	   a	   slight	  additional	  expression	  as	  seen	  in	  Western	  Blot	  and	  histogram,	  such	  as	  in	  G1	  GBA	  activity	   assay.	   The	   protein	   expression	   of	   Chaperone	   #3	   seems	   to	   be	   lower,	  almost	  unobservable	  unlike	  Chaperone	  #4,	  which	  presents	  a	  high	  expression	  in	  5µM	  concentration	  and	  somewhat	  in	  30µM	  concentration.	  Chaperone	  #3	  and	  #4	  are	  more	  or	   less	  according	   to	  GD1	  GBA	  activity	  assay,	  might	  had	  more	  protein	  quantity	  on	  the	  gel.	  Particularly,	  50µM	  concentration	  of	  Chaperone	  #4	  may	  have	  been	  lost	  on	  the	  gel	  or	  in	  transfer	  to	  the	  membrane.	  	   The	   strong	   protein	   expression	   observed	   in	   Chaperone	   #5	  Western	   Blot	  and	  histogram	  is	  more	   less	  as	  shown	   in	  GD1	  GBA	  activity	  assay.	  Chaperone	  #6	  and	   #7	   present	   some	   protein	   expression	   in	   Western	   Blot	   and	   histogram,	  according	   to	   GD1	   GBA	   activity	   assay.	   Except	   in	   Chaperone	   #6	   50µM	  concentration,	  which	  shows	  an	  increasing	  activity	  in	  GD1	  GBA	  activity	  assay	  and	  in	  Western	   Blot	   there	   is	   not	   so	  much	   protein	   expression.	   As	   in	   Chaperone	   #7	  protein	  activity	  seems	  to	  be	  higher	  than	  protein	  expression	  in	  Western	  Blot	  and	  histogram.	  There	   is	   some	  protein	   expression	  of	  Chaperone	  #8	   in	  Western	  Blot	  and	   histogram,	   being	   high	   in	   30µM	   concentration,	   comparing	   to	   GD1	   GBA	  activity	   assay.	   Once	   again,	   Chaperone	   #8	   50µM	   concentration	   in	  Western	   Blot	  seems	  to	  be	  lost	  in	  gel	  or	  in	  transfer.	  In	  general,	  GD1	  samples	  protein	  expression	  shown	  in	  Western	  Blot	   is	   in	  conformity	  with	  protein	  levels	  of	  GD1	  GBA	  activity	  assay.	  	  	  	   In	   the	   case	   of	   GD1	   fibroblasts	   (GDT2	   genotype	   N188S/G193W)	   treated	  with	  8	   chaperone	   compounds,	   the	   results	  we	  obtained	  on	   the	  GBA	  assay	  were	  confirmed	   by	   Western	   Blot,	   suggesting	   that	   the	   GBA	   assay	   was	   accurate.	  Therefore,	   for	  GD2,	  GD3	  and	  GD4	  fibroblasts	  we	  performed	  the	  GBA	  assays	  but	  did	  not	  confirm	  them	  by	  Western	  Blot.	   In	   the	   following	  section	  we	  present	   the	  final	  results	  of	  the	  GBA	  fluorometric	  assay	  for	  GD2,	  GD3	  and	  GD4	  fibroblasts	   in	  Figure	  18,	  Figure	  19	  and	  Figure	  20.	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Figure	   18	   -­‐	  Effect	   of	   chaperone	   1-­‐8	   on	   glucocerebrosidase	   activity	   of	  
fibroblasts	   (GD2)	   derived	   from	   a	   patient	   with	   GDT2	   with	   genotype	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Figure	   19	   -­‐	   Effect	   of	   chaperone	   1-­‐8	   on	   glucocerebrosidase	   activity	   of	  
fibroblasts	   (GD3)	   derived	   from	   a	   patient	   with	   GDT2	   with	   genotype	  
L444P/L444P.	   Protein	   activity	   of	   GD3	   fibroblasts	   treated	   with	   8	   different	  chaperones	   in	   different	   concentrations	   (5µM,	   30µM,	   50µM)	   compared	   to	  protein	   activity	   of	   GD3	   fibroblast	   control	   untreated	   sample	   (0).	   Results	  presented	  as	  histogram	  chart.	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Figure	   20	   -­‐	  Effect	   of	   chaperone	   1-­‐8	   on	   glucocerebrosidase	   activity	   of	  
fibroblasts	   (GD4)	   derived	   from	   a	   patient	   with	   GDT2	   with	   genotype	  
L444P/R120W.	  Protein	  activity	  of	  GD4	  fibroblasts	  treated	  with	  8	  different	  chaperones	   in	   different	   concentrations	   (5µM,	   30µM,	   50µM)	   compared	   to	  protein	   activity	   of	   GD4	   fibroblast	   control	   untreated	   sample	   (0).	   Results	  presented	  as	  histogram	  chart.	  	   	  	  Overall,	   our	   results	   indicate	   that	   several	   of	   the	   chaperone	   compounds	  tested	   increase	   protein	   activity	   in	   the	   GD1	   fibroblasts	   used	   in	   this	   study.	  Interestingly,	  this	  panel	  of	  chaperone	  compounds	  does	  not	  significantly	  improve	  protein	  activity	  in	  the	  GD2,	  GD3	  and	  GD4	  fibroblast	  lines	  tested,	  regardless	  of	  the	  concentration	   used.	   Compared	   to	   untreated	   cells,	   no	   increase	   in	  glucocerebrosidase	   activity	  was	  observed.	  Chaperone	   compound	  #5	   seemed	   to	  increase	  GBA	   activity	   in	   GD2	   fibroblasts	   at	   30	  µM	  by	   3	   fold.	   The	   fact	   that	   this	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increase	  was	  not	  observed	  at	  5	  µM	  or	  50	  µM	  makes	  this	  measurement	  doubtful.	  Indeed,	   a	   closer	   examination	   of	   the	   protein	   concentration	   reveals	   that	   this	  particular	  sample	  seemed	  to	  have	  a	  protein	  concentration	  that	  was	  significantly	  lower	   than	   for	   all	   other	   samples	   in	   the	   experiment,	   explaining	   why	   the	   GBA	  activity	   is	   so	   high	   when	   normalized	   to	   protein	   content.	   We	   suspect	   that	   the	  protein	   concentration	   value	   was	   incorrectly	   measured,	   and	   that	   overall,	   this	  chaperone	  has	  no	  effect	  on	  GBA	  activity	  of	  GD2	  fibroblasts.	  	  	  	  	  Nevertheless,	   the	  effect	  of	  chaperone	  compounds	  in	  GD1	  fibroblasts	  was	  in	  line	  with	  expectations.	  For	  several	  chaperone	  compounds	  an	  increase	  of	  GBA	  activity	   and	   stability	   was	   observed.	   In	   several	   cases,	   the	   increase	   was	  proportional	  to	  the	  concentration	  of	  chaperone.	  Our	  experiments	  would	  need	  to	  be	   repeated	   to	   confirm	   these	   results,	   and	   in	   that	   case,	   we	   would	   be	   able	   to	  confirm	   that	   the	   effect	   of	   a	   particular	   chaperone	   on	   glucocerebrosidase	   is	  dependent	  on	  the	  particular	  genotype.	  Possibly,	  different	  mutations	  affect	  the	  3D	  structure	   of	   the	   enzyme	   in	   different	   ways	   and	   different	   chaperones	   may	  therefore	  have	  different	  effects.	  In	  addition,	  the	  capability	  of	  glucocerebrosidase-­‐chaperone	   complex	   to	   be	   recognized	   as	   folded	   and	   transit	   through	   the	   ER	  depends	  on	  other	  constituents	  of	  each	  individuals’	  ER	  quality	  control	  machinery	  (Bendikov-­‐Bar,	   Maor,	   Filocamo,	   &	   Horowitz,	   2013).	   Consequently	   these	   facts	  may	   be	   the	   source	   differences	   in	   chaperone	   compounds	   effects	   on	  glucocerebrosidase	  activity	  of	  the	  samples	  used.	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Chapter	  4	  
Conclusion	  	   As	   it	   is	  known,	  GD	  presents	  both	  visceral	  and	  neuronopathic	  symptoms,	  thus,	   therapies	   that	   address	   both	   types	   of	   symptoms	   are	   needed.	   The	   use	   of	  chaperone	   compounds	   in	   this	   work	  was	  mainly	   with	   the	   aim	   to	   contribute	   to	  overcome	   certain	  difficulties	   in	  GD	   therapies	   for	   the	  neuronopathic	   symptoms.	  Four	   different	   fibroblasts	   lines	   from	   GD	   patients	   with	   different	   genotypes	   of	  GDT2	   were	   used	   in	   this	   study.	   These	   samples	   were	   tested	   with	   8	   different	  chaperone	   compounds	   to	  measure	   their	   glucocerebrosidase	   activity.	  According	  to	  our	  results,	  this	  method	  seems	  to	  be	  a	  promising	  approach	  in	  GD.	  	  The	   fibroblasts	   used	   were	   from	   GDT2	   patients	   with	   four	   different	  genotypes.	   Our	   results	   suggest	   that	   chaperones	   might	   be	   mutation	   specific	   in	  their	  effects,	  due	  to	  the	  differences	  found	  in	  results	  from	  patient	  sample	  GD1	  and	  from	  results	  in	  patient	  samples	  GD2-­‐GD4.	  Bendikov-­‐Bar	  et	  al.	  proposes	  that	  the	  ability	   of	   the	   protein-­‐chaperone	   complex	   to	   be	   recognized	   as	   folded	   and	   leave	  the	  ER	  is	  depending	  on	  components	  of	  the	  individuals’	  ER	  function.	  Furthermore,	  the	  increase	  in	  GBA	  activity	  observed	  for	  several	  chaperones	  in	  the	  case	  of	  GD1	  suggests	  that	  some	  of	  these	  compounds	  could	  be	  used	  in	  a	  potential	  therapy,	  as	  clinical	  data	   suggest	   that	  a	  modest	   increase	   in	  glucocerebrosidase	  activity	  may	  be	  enough	  to	  achieve	  a	  therapeutic	  effect	  (Sawkar	  et	  al.,	  2002;	  Yu	  et	  al.,	  2007).	  In	  addition,	   chaperones	   remove	  mutant	   protein	  molecules	   from	   ER	   and	   increase	  lysosomal	   protein	   activity.	   As	   well	   as	   reduce	   significantly	   the	   ER	   stress	   load	  caused	   by	   accumulation	   of	  misfolded	   protein	  molecules,	   therefore	   chaperones	  protect	  cells	  from	  the	  consequences	  of	  ER	  stress	  (Bendikov-­‐Bar	  et	  al.,	  2013).	  The	   research	   in	   this	   therapeutic	   approach	   must	   continued,	   once	   the	  response	   to	   chaperones	   seems	   to	   depend	   on	   patients	   mutations.	   Also,	   the	  identification	   of	   more	   potential	   chaperone	   compounds	   for	   mutant	   enzyme	  variants	  is	  a	  goal	  in	  developing	  this	  therapy	  (Bendikov-­‐Bar	  et	  al.,	  2013).	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Chapter	  5	  
	  
Future	  Perspectives	  	  	  	   In	  the	  near	  future,	  this	  approach	  and	  its	  techniques	  will	  be	  useful	  to	  test	  the	   effect	   of	   pharmacological	   chaperones	   in	   neurons	   derived	   from	   IPSc	   of	   GD	  patients.	   The	   goal	   is	   to	   determine	   its	   potential	   use	   for	   a	   GD	   therapy.	   These	  chaperones	   may	   be	   tested	   in	   neurons	   and	   can	   be	   a	   progress	   for	   neurological	  manifestations	   treatment	   in	   GD.	   Therefore	   this	   experimental	   work	   may	  contribute	  on	  the	  development	  of	  a	  prospective	  therapy	  for	  neuropathic	  forms	  of	  the	  disease.	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Annexes	  	  	  
RIPA	  reagent	  recipes:	  	  	  RIPA	  Base	  stock	  	  790mg	  TRIS-­‐Base;	  	  900mg	  NaCl;	  	  Dissolve	  in	  80ml;	  	  pH	  7.4	  (with	  HCL)	  	  Add	  10ml	  of	  10%	  Triton;	  	  Add	  2.5ml	  of	  10%	  Na-­‐deoxycholate	  solution;	  	  Top	  up	  to	  100ml.	  	  	  Active	  RIPA	  Buffer	  
	  To	  make	  active	  RIPA	  buffer;	  	  To	  20ml	  of	  RIPA	  stock,	  add	  the	  following;	  	  200ul	  of	  100mM	  EDTA	  stock;	  	  20ul	  of	  1000x	  P.I.C.	  solution;	  	  200ul	  of	  Na3VO4	  (sodium	  orthovanidate);	  	  1ml	  NaF	  (200mM	  stock);	  	  Once	  this	  RIPA	  is	  made	  it	  is	  good	  for	  about	  2	  months.	  	  	  	  
Bradford	  reagent	  recipe:	  	  Preparation	  of	  Bradford	  working	  dilution:	  Bradford	  Assay	  dye	  (BioRad	  #	  500-­‐0006)	  Dilute	  stock	  1/5	  in	  H2O,	  filter,	  store	  at	  4ºC,	  2	  weeks).	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GBA	  Assay	  reagent	  recipes:	  	  Glycine	  buffer:	  	  Prepare	   100ml	   of	   Glycine	   buffer:	   dissolve	   1.5g	   of	   glycine,	   1.32g	   of	   sodium	  carbonate,	  0.64g	  of	  NaOH	  in	  70ml	  mQ	  H20,	  adjust	  to	  100ml	  final	  volume	  with	  mQ	  H20;	  	  	  Substrate	  solution:	  	  	  Prepare	   100ml	   of	   Substrate	   solution:	   0.169g	   of	   4	   MU-­‐B-­‐D	   glucosylpiranoside	  mw:	  338.3	  g/mol,	  100ul	  of	  Triton	  X,	  0.3g	  of	  Taurocholate,	   in	  Phosphate/Citrate	  buffer	  ph	  5.8	  (adapt	  values,	  calculate	  the	  amount	  you	  need	  in	  X	  g	  of	  4MUBD);	  	  	  4	  methylumbelliferyl	  (4MU):	  	  Prepare	   a	   142mM	  solution	   of	   4	  methylumbelliferyl	   (4MU)	   in	   absolute	   ethanol:	  weigh	  24.9	  mg	  of	  4MU	  and	  dissolve	  in	  1ml	  of	  EtOH,	  dilute	  1/100	  +	  1/100	  +	  1/10	  (using	  ethanol),	  this	  will	  give	  you	  a	  solution	  of	  1.42	  nmol/ul.	  	  	  	  
Western	  Blot	  buffers	  recipes:	  	   Running	  Buffer	  10x	  
	  10g	  SDS	  30,3g	  Tris	  144,1g	  Glycine	  	  800ml	  H2O	  	  Up	  to	  1L	  once	  dissolved.	  	   	  Transfer	  Buffer	  1X	  
	  2,9g	  Glycine	  5,8g	  Tris	  0,37g	  SDS	  	  200ml	  Methanol	  	  Up	  to	  1L	  (H2O).	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Western	  Blot	  Antibodies:	  	  
AntiGBA	  AB4	  -­‐	  Mouse	  monoclonal	  to	  GBA	  1x100	  ug;	  abcam®discovermore;	  Ref.:	  798203747835;	  Product:	  ab55080;	  Dilution:	  6ul	  AB	  in	  6ml	  BSA	  blocking	  solution.	  	  AB6	  -­‐	  Goat	  anti-­‐mouse	  IgG	  peroxidase-­‐conjugated	  0,8	  mg/ml;	  Affinipure®;	  115-­‐035-­‐003;	  Dilution:	  1ul	  AB	  in	  10ml	  BSA	  blocking	  solution.	  	  	  
AntiActin	  Actin	  (I-­‐19):	  sc-­‐1616	  -­‐	  Actin	  goat	  polyclonal;	  Santa	  Cruz	  Biotechnology,	  Inc®;	  Molecular	  Weigh:	  43	  kDA;	  starting	  dilution	  1:200,	  dilution	  range	  1:100	  -­‐	  1:1000;	  diluted	  in	  BSA	  blocking	  solution.	  	  Goat	  anti	  mouse	  IgG-­‐HRP:	  sc-­‐2005;	  Santa	  Cruz	  Biotechnology,	  Inc	  ®;	  dilution:	  1:5000.	  	  	  Western	  Blot	  ECL:	  Amersham	  ECL	  Prime	  Western	  Blotting	  Detection	  Reagent;	  Detection	  reagent	  1	  and	  detection	  reagent	  2;	  code	  number:	  RPN	  2232;	  Dilute	  1:2	  PBS.	  	  Western	  Blot	  Revelation:	  ChemiDoc	  (BIORAD®);	  Software:	  Image	  Lab	  5.1	  –	  Beta.	  
